| 1 |
Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.Prostate. 2008 Sep 15;68(13):1421-9. doi: 10.1002/pros.20809.
|
| 2 |
ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors.BMC Cancer. 2010 Jun 14;10:288. doi: 10.1186/1471-2407-10-288.
|
| 3 |
Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer.Oncotarget. 2014 Sep 30;5(18):8681-9. doi: 10.18632/oncotarget.2365.
|
| 4 |
Aryl hydrocarbon receptor signaling involved in the invasiveness of LNCaP cells.Hum Cell. 2017 Apr;30(2):133-139. doi: 10.1007/s13577-016-0158-2. Epub 2017 Jan 16.
|
| 5 |
The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells.J Biol Chem. 2015 Aug 21;290(34):20865-20879. doi: 10.1074/jbc.M115.662155. Epub 2015 Jul 9.
|
| 6 |
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.Cancers (Basel). 2019 Nov 13;11(11):1785. doi: 10.3390/cancers11111785.
|
| 7 |
Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
|
| 8 |
Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity.Oncotarget. 2015 Jan 20;6(2):1302-14. doi: 10.18632/oncotarget.2744.
|
| 9 |
Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells.Int J Cancer. 2009 Jan 1;124(1):68-74. doi: 10.1002/ijc.23928.
|
| 10 |
Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.Prostate. 2013 Apr;73(5):455-66. doi: 10.1002/pros.22587. Epub 2012 Oct 4.
|
| 11 |
KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3.J Biol Chem. 2008 Oct 31;283(44):29795-801. doi: 10.1074/jbc.M802515200. Epub 2008 Aug 28.
|
| 12 |
The long tail of oncogenic drivers in prostate cancer.Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2.
|
| 13 |
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4.
|
| 14 |
Functional analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.Neoplasia. 2007 Sep;9(9):707-15. doi: 10.1593/neo.07322.
|
| 15 |
Integrative molecular concept modeling of prostate cancer progression.Nat Genet. 2007 Jan;39(1):41-51. doi: 10.1038/ng1935. Epub 2006 Dec 17.
|
| 16 |
Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells.Clin Cancer Res. 2008 Sep 1;14(17):5341-7. doi: 10.1158/1078-0432.CCR-08-0793.
|
| 17 |
Bad expression influences time to androgen escape in prostate cancer.BJU Int. 2007 Sep;100(3):691-6. doi: 10.1111/j.1464-410X.2007.07001.x. Epub 2007 Jun 2.
|
| 18 |
BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence.Nat Genet. 2015 Jan;47(1):22-30. doi: 10.1038/ng.3165. Epub 2014 Dec 8.
|
| 19 |
FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-X(L) cell survival genes.BMC Cancer. 2018 Jan 22;18(1):90. doi: 10.1186/s12885-017-3950-9.
|
| 20 |
APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells. Oncotarget. 2017 Dec 13;9(13):10962-10977. doi: 10.18632/oncotarget.23493. eCollection 2018 Feb 16.
|
| 21 |
Comparative RNA-seq analysis reveals dys-regulation of major canonical pathways in ERG-inducible LNCaP cell progression model of prostate cancer.Oncotarget. 2019 Jul 2;10(42):4290-4306. doi: 10.18632/oncotarget.27019. eCollection 2019 Jul 2.
|
| 22 |
Suppressive roles of calreticulin in prostate cancer growth and metastasis.Am J Pathol. 2009 Aug;175(2):882-90. doi: 10.2353/ajpath.2009.080417. Epub 2009 Jul 16.
|
| 23 |
Global analysis of differentially expressed genes in androgen-independent prostate cancer.Prostate Cancer Prostatic Dis. 2007;10(2):167-74. doi: 10.1038/sj.pcan.4500933. Epub 2007 Jan 2.
|
| 24 |
Progression-Related Loss of Stromal Caveolin 1 Levels Mediates Radiation Resistance in Prostate Carcinoma via the Apoptosis Inhibitor TRIAP1.J Clin Med. 2019 Mar 12;8(3):348. doi: 10.3390/jcm8030348.
|
| 25 |
Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.Clin Cancer Res. 2007 Apr 15;13(8):2354-61. doi: 10.1158/1078-0432.CCR-06-1692. Epub 2007 Apr 3.
|
| 26 |
The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer.Cancers (Basel). 2019 Aug 16;11(8):1194. doi: 10.3390/cancers11081194.
|
| 27 |
Integrative molecular profiling of routine clinical prostate cancer specimens.Ann Oncol. 2015 Jun;26(6):1110-1118. doi: 10.1093/annonc/mdv134. Epub 2015 Mar 3.
|
| 28 |
Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis.Cancer Res. 2009 Feb 1;69(3):785-93. doi: 10.1158/0008-5472.CAN-08-1946. Epub 2009 Jan 20.
|
| 29 |
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.Mol Cell Endocrinol. 2012 Apr 4;351(2):249-63. doi: 10.1016/j.mce.2011.12.015. Epub 2012 Jan 8.
|
| 30 |
Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.Oncotarget. 2014 Jul 15;5(13):4895-908. doi: 10.18632/oncotarget.2052.
|
| 31 |
Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.Pharmacogenet Genomics. 2011 Oct;21(10):615-23. doi: 10.1097/FPC.0b013e3283493a57.
|
| 32 |
Association between CYP2E1 polymorphisms and susceptibility to prostate cancer.Eur J Cancer Prev. 2003 Jun;12(3):205-11. doi: 10.1097/00008469-200306000-00007.
|
| 33 |
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.Am J Epidemiol. 2004 Nov 1;160(9):825-41. doi: 10.1093/aje/kwh294.
|
| 34 |
Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells.J Cell Physiol. 2007 Nov;213(2):528-39. doi: 10.1002/jcp.21130.
|
| 35 |
The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.Cell Death Dis. 2014 Apr 24;5(4):e1195. doi: 10.1038/cddis.2014.157.
|
| 36 |
Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.Cancer Prev Res (Phila). 2012 Jul;5(7):963-72. doi: 10.1158/1940-6207.CAPR-12-0023. Epub 2012 May 11.
|
| 37 |
Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk.Oncol Rep. 2005 Aug;14(2):569-73.
|
| 38 |
Increased expression of p21Waf1/Cip1 and JNK with costimulation of prostate cancer cell activation by an siRNA Egr-1 inhibitor.Oncol Rep. 2013 Aug;30(2):911-6. doi: 10.3892/or.2013.2503. Epub 2013 May 28.
|
| 39 |
PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.Oncotarget. 2017 Apr 11;8(15):24046-24062. doi: 10.18632/oncotarget.15733.
|
| 40 |
Endoglin regulates cancer-stromal cell interactions in prostate tumors.Cancer Res. 2011 May 15;71(10):3482-93. doi: 10.1158/0008-5472.CAN-10-2665. Epub 2011 Mar 28.
|
| 41 |
HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.Cancer Res. 2017 Jan 1;77(1):74-85. doi: 10.1158/0008-5472.CAN-16-1656. Epub 2016 Oct 28.
|
| 42 |
Activation of AKR1C1/ER induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.Oncotarget. 2015 May 10;6(13):11600-13. doi: 10.18632/oncotarget.3417.
|
| 43 |
SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.Oncogene. 2017 Mar;36(10):1364-1373. doi: 10.1038/onc.2016.300. Epub 2016 Nov 21.
|
| 44 |
Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5463-73. doi: 10.1158/1078-0432.CCR-07-0342.
|
| 45 |
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.Nat Genet. 2011 Jul 10;43(8):785-91. doi: 10.1038/ng.882.
|
| 46 |
Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.J Nucl Med. 2020 Jan;61(1):70-79. doi: 10.2967/jnumed.119.229054. Epub 2019 Sep 20.
|
| 47 |
Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):169-73. doi: 10.1158/1055-9965.EPI-06-0320.
|
| 48 |
Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.J Clin Endocrinol Metab. 2002 Oct;87(10):4707-14. doi: 10.1210/jc.2002-020347.
|
| 49 |
Combination of non-viral connexin 43 gene therapy and docetaxel inhibits the growth of human prostate cancer in mice.Int J Oncol. 2007 Jan;30(1):225-31.
|
| 50 |
Distinct expression and activity of GSK-3 and GSK-3 in prostate cancer.Int J Cancer. 2012 Sep 15;131(6):E872-83. doi: 10.1002/ijc.27620. Epub 2012 May 22.
|
| 51 |
Human glutathione S-transferase A1, T1, M1, and P1 polymorphisms and susceptibility to prostate cancer in the Japanese population.J Cancer Res Clin Oncol. 2005 Apr;131(4):238-42. doi: 10.1007/s00432-004-0634-z. Epub 2004 Dec 23.
|
| 52 |
Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.Cell Commun Signal. 2017 Oct 10;15(1):40. doi: 10.1186/s12964-017-0197-7.
|
| 53 |
Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.PLoS One. 2014 May 14;9(5):e97771. doi: 10.1371/journal.pone.0097771. eCollection 2014.
|
| 54 |
Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1 in Prostate Cancer Cells.Mol Cancer Ther. 2020 Apr;19(4):1008-1017. doi: 10.1158/1535-7163.MCT-19-0777. Epub 2019 Dec 17.
|
| 55 |
Early detection of prostate carcinogens by immunohistochemistry of HMGB2.J Toxicol Sci. 2018;43(6):359-367. doi: 10.2131/jts.43.359.
|
| 56 |
Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):969-78. doi: 10.1158/1055-9965.EPI-06-0767.
|
| 57 |
Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer.Clin Exp Metastasis. 2008;25(5):497-508. doi: 10.1007/s10585-008-9157-3. Epub 2008 Mar 14.
|
| 58 |
Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.Sci Rep. 2016 Aug 24;6:31842. doi: 10.1038/srep31842.
|
| 59 |
BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype.J Pathol. 2008 Feb;214(3):394-404. doi: 10.1002/path.2292.
|
| 60 |
Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population.PLoS One. 2014 Feb 21;9(2):e85609. doi: 10.1371/journal.pone.0085609. eCollection 2014.
|
| 61 |
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.Oncogene. 2003 Feb 20;22(7):1024-34. doi: 10.1038/sj.onc.1206210.
|
| 62 |
Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer.DNA Cell Biol. 2007 Aug;26(8):613-8. doi: 10.1089/dna.2007.0600.
|
| 63 |
The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2563-8. doi: 10.1158/1055-9965.EPI-05-0356.
|
| 64 |
Making an avipoxvirus encoding a tumor-associated antigen and a costimulatory molecule.Methods Mol Biol. 2014;1139:407-27. doi: 10.1007/978-1-4939-0345-0_32.
|
| 65 |
Pigment epithelial-derived factor and melanoma differentiation associated gene-7 cytokine gene therapies delivered by adipose-derived stromal/mesenchymal stem cells are effective in reducing prostate cancer cell growth.Stem Cells Dev. 2012 May 1;21(7):1112-23. doi: 10.1089/scd.2011.0247. Epub 2011 Jul 26.
|
| 66 |
Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth.Theranostics. 2019 Jan 25;9(3):853-867. doi: 10.7150/thno.29553. eCollection 2019.
|
| 67 |
Polymorphism of the insulin gene is associated with increased prostate cancer risk.Br J Cancer. 2003 Jan 27;88(2):263-9. doi: 10.1038/sj.bjc.6600747.
|
| 68 |
Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts.J Cancer Res Clin Oncol. 2008 Aug;134(8):833-9. doi: 10.1007/s00432-008-0359-5. Epub 2008 Feb 9.
|
| 69 |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.Prostate. 2007 Jan 1;67(1):83-106. doi: 10.1002/pros.20505.
|
| 70 |
Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.Prostate. 2011 Dec;71(16):1780-9. doi: 10.1002/pros.21395. Epub 2011 Apr 25.
|
| 71 |
Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.Prostate. 2009 Feb 15;69(3):283-92. doi: 10.1002/pros.20879.
|
| 72 |
Genetic and epigenetic inactivation of LPL gene in human prostate cancer.Int J Cancer. 2009 Feb 1;124(3):734-8. doi: 10.1002/ijc.23972.
|
| 73 |
The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.J Cancer Epidemiol. 2012;2012:358076. doi: 10.1155/2012/358076. Epub 2012 Aug 2.
|
| 74 |
Mutant L Homologue 1 (MLH1): a possible new immunohistochemical marker for prostatic cancer.Histopathology. 2008 Jan;52(2):247-50. doi: 10.1111/j.1365-2559.2007.02879.x. Epub 2007 Nov 13.
|
| 75 |
Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer.Oncol Rep. 2004 Jun;11(6):1187-92.
|
| 76 |
Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.Cancer Sci. 2017 Apr;108(4):744-752. doi: 10.1111/cas.13187. Epub 2017 Apr 12.
|
| 77 |
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.BMC Cancer. 2018 Jan 2;18(1):8. doi: 10.1186/s12885-017-3976-z.
|
| 78 |
Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression.Cancer Res. 2008 Jul 1;68(13):5460-8. doi: 10.1158/0008-5472.CAN-08-0955.
|
| 79 |
Epigenetic reactivation of Nrf2 in murine prostate cancer TRAMP C1 cells by natural phytochemicals Z-ligustilide and Radix angelica sinensis via promoter CpG demethylation.Chem Res Toxicol. 2013 Mar 18;26(3):477-85. doi: 10.1021/tx300524p. Epub 2013 Mar 8.
|
| 80 |
Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.Cancer Res. 2010 Oct 15;70(20):8088-96. doi: 10.1158/0008-5472.CAN-10-1418. Epub 2010 Oct 12.
|
| 81 |
The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.Int J Cancer. 2015 Feb 15;136(4):E27-38. doi: 10.1002/ijc.29147. Epub 2014 Aug 27.
|
| 82 |
Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16.
|
| 83 |
Association between polymorphism of human oxoguanine glycosylase 1 and risk of prostate cancer.J Urol. 2003 Dec;170(6 Pt 1):2471-4. doi: 10.1097/01.ju.0000087498.23008.bb.
|
| 84 |
Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.ACS Med Chem Lett. 2019 Mar 13;10(4):534-538. doi: 10.1021/acsmedchemlett.8b00569. eCollection 2019 Apr 11.
|
| 85 |
Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.APMIS. 2009 Mar;117(3):151-61. doi: 10.1111/j.1600-0463.2008.00002.x.
|
| 86 |
Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells.Mol Pharm. 2014 Oct 6;11(10):3443-51. doi: 10.1021/mp500174p. Epub 2014 Sep 22.
|
| 87 |
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.Nat Genet. 2018 Feb;50(2):206-218. doi: 10.1038/s41588-017-0027-2. Epub 2018 Jan 15.
|
| 88 |
Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells.Mol Endocrinol. 2006 Dec;20(12):3053-69. doi: 10.1210/me.2006-0033. Epub 2006 Aug 24.
|
| 89 |
NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer.Oncotarget. 2014 Nov 30;5(22):11081-90. doi: 10.18632/oncotarget.2404.
|
| 90 |
COX-2 mediates pro-tumorigenic effects of PKC in prostate cancer.Oncogene. 2018 Aug;37(34):4735-4749. doi: 10.1038/s41388-018-0318-9. Epub 2018 May 16.
|
| 91 |
Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker.Oncol Rep. 2009 Jan;21(1):95-100.
|
| 92 |
Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.Urol Oncol. 2016 Oct;34(10):431.e1-8. doi: 10.1016/j.urolonc.2016.05.018. Epub 2016 Jun 16.
|
| 93 |
Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.Cancer Res. 2007 Oct 1;67(19):9089-96. doi: 10.1158/0008-5472.CAN-07-2887.
|
| 94 |
Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res. 2011 Mar;50(2):140-9. doi: 10.1111/j.1600-079X.2010.00823.x. Epub 2010 Nov 9.
|
| 95 |
Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.Oncogene. 2017 Jul 27;36(30):4299-4310. doi: 10.1038/onc.2017.64. Epub 2017 Mar 27.
|
| 96 |
A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.Cancer Gene Ther. 2012 Dec;19(12):839-44. doi: 10.1038/cgt.2012.68. Epub 2012 Oct 5.
|
| 97 |
CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun. 2001 Apr 6;282(3):729-34.
|
| 98 |
Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.Oncogene. 2019 Sep;38(38):6507-6520. doi: 10.1038/s41388-019-0901-8. Epub 2019 Jul 29.
|
| 99 |
DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.Prostate. 2015 Nov;75(15):1790-801. doi: 10.1002/pros.23052. Epub 2015 Sep 1.
|
| 100 |
Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling.Cell Commun Signal. 2019 Sep 18;17(1):120. doi: 10.1186/s12964-019-0410-y.
|
| 101 |
Six-Transmembrane Epithelial Antigen of the Prostate-1 (STEAP-1)-Targeted Ultrasound Imaging Microbubble Improves Detection of Prostate Cancer In Vivo.J Ultrasound Med. 2019 Feb;38(2):299-305. doi: 10.1002/jum.14689. Epub 2018 Jul 19.
|
| 102 |
Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.Prostate. 2010 May 1;70(6):630-45. doi: 10.1002/pros.21097.
|
| 103 |
Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu).Tumori. 2010 Sep-Oct;96(5):645-9. doi: 10.1177/030089161009600501.
|
| 104 |
TLR4 signaling promotes the expression of VEGF and TGFbeta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide.Cell Immunol. 2008;254(1):20-7. doi: 10.1016/j.cellimm.2008.06.007. Epub 2008 Jul 22.
|
| 105 |
Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk.Int J Cancer. 2008 Dec 1;123(11):2644-50. doi: 10.1002/ijc.23826.
|
| 106 |
The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.Prostate. 2008 Feb 15;68(3):264-8. doi: 10.1002/pros.20682.
|
| 107 |
The secreted matrix protein mindin increases prostate tumor progression and tumor-bone crosstalk via ERK 1/2 regulation.Carcinogenesis. 2019 Jul 20;40(7):828-839. doi: 10.1093/carcin/bgz105.
|
| 108 |
Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.Cancer Res. 2007 Mar 15;67(6):2893-8. doi: 10.1158/0008-5472.CAN-06-2962.
|
| 109 |
PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells.Int J Mol Med. 2007 Jul;20(1):11-20.
|
| 110 |
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.Prostate Cancer Prostatic Dis. 2005;8(3):260-5. doi: 10.1038/sj.pcan.4500817.
|
| 111 |
Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer.Oncol Rep. 2009 Jan;21(1):33-7.
|
| 112 |
Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging-related prostate lesions.Prostate. 2018 May;78(7):532-546. doi: 10.1002/pros.23498. Epub 2018 Mar 5.
|
| 113 |
Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer.Oncotarget. 2016 Jul 12;7(28):44350-44364. doi: 10.18632/oncotarget.10051.
|
| 114 |
Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.Prostate. 2009 May 15;69(7):774-86. doi: 10.1002/pros.20930.
|
| 115 |
Activation of -Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer.Cancer Res. 2020 Feb 1;80(3):576-590. doi: 10.1158/0008-5472.CAN-19-1684. Epub 2019 Nov 12.
|
| 116 |
Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene.Genes Chromosomes Cancer. 2016 Aug;55(8):661-73. doi: 10.1002/gcc.22368. Epub 2016 May 24.
|
| 117 |
Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis.Mol Cancer Ther. 2008 May;7(5):1227-36. doi: 10.1158/1535-7163.MCT-08-0051.
|
| 118 |
Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.Genes Chromosomes Cancer. 2015 Jan;54(1):51-62. doi: 10.1002/gcc.22218. Epub 2014 Sep 18.
|
| 119 |
Calcitonin promotes in vivo metastasis of prostate cancer cells by altering cell signaling, adhesion, and inflammatory pathways.Endocr Relat Cancer. 2008 Dec;15(4):953-64. doi: 10.1677/ERC-08-0136. Epub 2008 Sep 10.
|
| 120 |
Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008 Nov 27;27(56):7106-17. doi: 10.1038/onc.2008.318. Epub 2008 Sep 8.
|
| 121 |
Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.Prostate. 2009 Apr 1;69(5):520-7. doi: 10.1002/pros.20901.
|
| 122 |
Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.Sci Rep. 2017 Aug 3;7(1):7190. doi: 10.1038/s41598-017-05685-3.
|
| 123 |
Fibroblast growth factor and ornithine decarboxylase 5'UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN(-/-) transgenic mice.Cancer Gene Ther. 2012 Jan;19(1):19-29. doi: 10.1038/cgt.2011.62. Epub 2011 Sep 16.
|
| 124 |
CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer.Theranostics. 2017 Jan 1;7(1):67-80. doi: 10.7150/thno.16752. eCollection 2017.
|
| 125 |
Cooperation between ETS variant 2 and Jumonji domaincontaining 2 histone demethylases.Mol Med Rep. 2018 Apr;17(4):5518-5527. doi: 10.3892/mmr.2018.8507. Epub 2018 Jan 26.
|
| 126 |
Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer.Oncogene. 2010 May 27;29(21):3067-78. doi: 10.1038/onc.2010.97. Epub 2010 Apr 12.
|
| 127 |
Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.Oncogene. 2017 Feb 2;36(5):687-699. doi: 10.1038/onc.2016.240. Epub 2016 Jul 4.
|
| 128 |
Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer.Eur J Surg Oncol. 2008 Jul;34(7):805-10. doi: 10.1016/j.ejso.2007.09.008. Epub 2007 Oct 29.
|
| 129 |
The role of PIM1/PIM2 kinases in tumors of the male reproductive system.Sci Rep. 2016 Nov 30;6:38079. doi: 10.1038/srep38079.
|
| 130 |
Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J. 2013 Apr;13(2):110-20.
|
| 131 |
Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.Mol Cancer Res. 2012 Jun;10(6):821-33. doi: 10.1158/1541-7786.MCR-11-0615. Epub 2012 Mar 27.
|
| 132 |
Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):23-30. doi: 10.1097/PAI.0b013e31817c3334.
|
| 133 |
The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.Oncogene. 2012 Nov 15;31(46):4878-87. doi: 10.1038/onc.2011.641. Epub 2012 Feb 13.
|
| 134 |
Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT).Prostate. 2008 Jan 1;68(1):20-33. doi: 10.1002/pros.20674.
|
| 135 |
Analysis of cholinesterases in human prostate and sperm: implications in cancer and fertility.Chem Biol Interact. 2010 Sep 6;187(1-3):432-5. doi: 10.1016/j.cbi.2010.03.038. Epub 2010 Mar 29.
|
| 136 |
Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells.Cancer Genet Cytogenet. 2005 Dec;163(2):123-9. doi: 10.1016/j.cancergencyto.2005.05.007.
|
| 137 |
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.Eur Urol. 2008 Nov;54(5):1097-106. doi: 10.1016/j.eururo.2007.11.034. Epub 2007 Nov 26.
|
| 138 |
The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican.Prostate. 2005 May 15;63(3):269-75. doi: 10.1002/pros.20182.
|
| 139 |
PACAP and type I PACAP receptors in human prostate cancer tissue.Ann N Y Acad Sci. 2006 Jul;1070:440-9. doi: 10.1196/annals.1317.059.
|
| 140 |
PAC1-R null isoform expression in human prostate cancer tissue.Prostate. 2006 Apr 1;66(5):514-21. doi: 10.1002/pros.20356.
|
| 141 |
Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
|
| 142 |
Case-only gene-environment interaction between ALAD tagSNPs and occupational lead exposure in prostate cancer.Prostate. 2014 May;74(6):637-46. doi: 10.1002/pros.22781. Epub 2014 Feb 5.
|
| 143 |
Activated leukocyte cell adhesion molecule: a new paradox in cancer.Transl Res. 2008 Mar;151(3):122-8. doi: 10.1016/j.trsl.2007.09.006. Epub 2007 Oct 23.
|
| 144 |
Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem. 2006 Jul 7;281(27):18601-9. doi: 10.1074/jbc.M601887200. Epub 2006 Apr 25.
|
| 145 |
Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer.Int J Cancer. 2009 Apr 1;124(7):1545-51. doi: 10.1002/ijc.24118.
|
| 146 |
Analysis of bone alkaline phosphatase as a marker for the diagnosis of osteoporosis in men under androgen ablation.Int J Biol Markers. 2003 Oct-Dec;18(4):290-4. doi: 10.1177/172460080301800407.
|
| 147 |
Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus.Prostate. 2008 Sep 1;68(12):1354-61. doi: 10.1002/pros.20800.
|
| 148 |
Elevated expression of angiogenin in prostate cancer and its precursors.Clin Cancer Res. 2005 Dec 1;11(23):8358-63. doi: 10.1158/1078-0432.CCR-05-0962.
|
| 149 |
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Nat Genet. 2018 May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. Epub 2018 Apr 16.
|
| 150 |
Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1.Mol Cell Biochem. 2016 Jan;411(1-2):11-21. doi: 10.1007/s11010-015-2564-2. Epub 2015 Sep 14.
|
| 151 |
Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer.J Cell Biochem. 2008 Oct 1;105(2):370-80. doi: 10.1002/jcb.21835.
|
| 152 |
Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.Infect Agent Cancer. 2009 Feb 10;4 Suppl 1(Suppl 1):S3. doi: 10.1186/1750-9378-4-S1-S3.
|
| 153 |
Expression of aquaporin 3 in the human prostate.Int J Urol. 2007 Dec;14(12):1088-92; discussion 1092. doi: 10.1111/j.1442-2042.2007.01901.x.
|
| 154 |
Rapid Development of Spinal Epidural Lipomatosis after Treatment of Metastatic Castration-Resistant Prostate Cancer with Second-Generation Androgen Receptor Antagonists.World Neurosurg. 2019 May;125:222-227. doi: 10.1016/j.wneu.2019.01.222. Epub 2019 Feb 11.
|
| 155 |
Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One. 2013;8(2):e55146.
|
| 156 |
Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter.Prostate. 2004 Jun 1;59(4):370-82. doi: 10.1002/pros.20010.
|
| 157 |
Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014 Oct 15;74(20):5819-31. doi: 10.1158/0008-5472.CAN-13-3527.
|
| 158 |
Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells.Front Oncol. 2017 Jan 30;7:11. doi: 10.3389/fonc.2017.00011. eCollection 2017.
|
| 159 |
Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.Prostate. 2008 Mar 1;68(4):453-61. doi: 10.1002/pros.20723.
|
| 160 |
Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.Prostate. 2008 Sep 1;68(12):1341-53. doi: 10.1002/pros.20799.
|
| 161 |
The prognostic significance of BMP-6 signaling in prostate cancer.Mod Pathol. 2008 Dec;21(12):1436-43. doi: 10.1038/modpathol.2008.94. Epub 2008 Oct 17.
|
| 162 |
Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.Neoplasia. 2010 Feb;12(2):192-205. doi: 10.1593/neo.91836.
|
| 163 |
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.Int J Oncol. 2007 Feb;30(2):521-9.
|
| 164 |
The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.Oncogene. 2006 Jan 5;25(1):70-8. doi: 10.1038/sj.onc.1209058.
|
| 165 |
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.Br J Cancer. 2009 Jan 27;100(2):426-30. doi: 10.1038/sj.bjc.6604847. Epub 2009 Jan 6.
|
| 166 |
CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.BMC Cancer. 2015 Jul 25;15:549. doi: 10.1186/s12885-015-1559-4.
|
| 167 |
CaV3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells.J Biol Chem. 2008 Apr 11;283(15):10162-73. doi: 10.1074/jbc.M707159200. Epub 2008 Jan 29.
|
| 168 |
Multiparametric magnetic resonance imaging of the prostate with computer-aided detection: experienced observer performance study.Eur Radiol. 2017 Oct;27(10):4200-4208. doi: 10.1007/s00330-017-4805-0. Epub 2017 Apr 6.
|
| 169 |
Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.
|
| 170 |
Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells. J Cell Physiol. 2008 Dec;217(3):569-76. doi: 10.1002/jcp.21565.
|
| 171 |
Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability.Prostate. 2006 Sep 1;66(12):1292-301. doi: 10.1002/pros.20438.
|
| 172 |
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.Br J Cancer. 2008 Dec 2;99(11):1849-58. doi: 10.1038/sj.bjc.6604774. Epub 2008 Nov 11.
|
| 173 |
Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.Clin Cancer Res. 2015 Dec 15;21(24):5619-29. doi: 10.1158/1078-0432.CCR-15-0744. Epub 2015 Aug 5.
|
| 174 |
Cyclin D3 action in androgen receptor regulation and prostate cancer.Oncogene. 2008 May 15;27(22):3111-21. doi: 10.1038/sj.onc.1210981. Epub 2007 Dec 17.
|
| 175 |
Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145.Oncol Rep. 2006 Oct;16(4):831-6.
|
| 176 |
Expression and functional role of CCR9 in prostate cancer cell migration and invasion.Clin Cancer Res. 2004 Dec 15;10(24):8743-50. doi: 10.1158/1078-0432.CCR-04-0266.
|
| 177 |
Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.Clin Cancer Res. 2016 May 15;22(10):2545-54. doi: 10.1158/1078-0432.CCR-15-1927. Epub 2015 Dec 28.
|
| 178 |
Identification of targets for prostate cancer immunotherapy.Prostate. 2019 Apr;79(5):498-505. doi: 10.1002/pros.23756. Epub 2019 Jan 6.
|
| 179 |
Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.Neoplasia. 2006 Jan;8(1):69-78. doi: 10.1593/neo.05679.
|
| 180 |
Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells.J Immunol. 2006 Dec 15;177(12):8730-9. doi: 10.4049/jimmunol.177.12.8730.
|
| 181 |
Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells.Prostate. 2004 Jan 1;58(1):95-102. doi: 10.1002/pros.10292.
|
| 182 |
Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer.Oncogene. 2003 Feb 6;22(5):734-9. doi: 10.1038/sj.onc.1206121.
|
| 183 |
Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer.Clin Cancer Res. 2005 Jul 1;11(13):4701-6. doi: 10.1158/1078-0432.CCR-04-2551.
|
| 184 |
Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.Cancer Res. 2007 Dec 15;67(24):11942-50. doi: 10.1158/0008-5472.CAN-07-3162.
|
| 185 |
Cadherin-11 promotes the metastasis of prostate cancer cells to bone.Mol Cancer Res. 2008 Aug;6(8):1259-67. doi: 10.1158/1541-7786.MCR-08-0077.
|
| 186 |
Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer.Oncotarget. 2016 Feb 9;7(6):6835-46. doi: 10.18632/oncotarget.6899.
|
| 187 |
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes.Mol Ther. 2010 Jan;18(1):181-7. doi: 10.1038/mt.2009.207. Epub 2009 Sep 8.
|
| 188 |
Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.J Biol Chem. 2004 Jul 9;279(28):29302-7. doi: 10.1074/jbc.M403664200. Epub 2004 Apr 30.
|
| 189 |
Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer.Oncotarget. 2016 Jul 26;7(30):48011-48026. doi: 10.18632/oncotarget.10333.
|
| 190 |
CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer.Oncogene. 2006 Aug 17;25(36):4965-74. doi: 10.1038/sj.onc.1209514. Epub 2006 Mar 27.
|
| 191 |
Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans.Mol Carcinog. 2019 Jun;58(6):854-861. doi: 10.1002/mc.23002. Epub 2019 Mar 11.
|
| 192 |
CGA gene (coding for the alpha subunit of glycoprotein hormones) overexpression in ER alpha-positive prostate tumors.Eur Urol. 2002 Mar;41(3):335-41. doi: 10.1016/s0302-2838(02)00020-9.
|
| 193 |
Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.Cancer Lett. 2008 Oct 18;270(1):173-80. doi: 10.1016/j.canlet.2008.05.006. Epub 2008 Jun 20.
|
| 194 |
Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.Urol Oncol. 2008 Jan-Feb;26(1):47-52. doi: 10.1016/j.urolonc.2007.07.020.
|
| 195 |
Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis.Cancer Res. 2005 Jul 1;65(13):5647-53. doi: 10.1158/0008-5472.CAN-04-4416.
|
| 196 |
The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.Prostate. 2009 Mar 1;69(4):443-8. doi: 10.1002/pros.20892.
|
| 197 |
TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells.BMC Cancer. 2008 Oct 3;8:282. doi: 10.1186/1471-2407-8-282.
|
| 198 |
Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.Am J Physiol Cell Physiol. 2007 Jun;292(6):C2288-96. doi: 10.1152/ajpcell.00503.2006. Epub 2007 Feb 28.
|
| 199 |
Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene. 2009 Aug 6;28(31):2829-38. doi: 10.1038/onc.2009.134. Epub 2009 Jun 8.
|
| 200 |
Macrophage cathepsin K promotes prostate tumor progression in bone.Oncogene. 2013 Mar 21;32(12):1580-93. doi: 10.1038/onc.2012.166. Epub 2012 May 21.
|
| 201 |
CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells.Cancer Sci. 2008 Jul;99(7):1362-9. doi: 10.1111/j.1349-7006.2008.00833.x. Epub 2008 Apr 29.
|
| 202 |
Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation.Oncotarget. 2017 Jun 13;8(24):39087-39100. doi: 10.18632/oncotarget.16598.
|
| 203 |
The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.Int J Cancer. 2008 Jun 1;122(11):2511-6. doi: 10.1002/ijc.23425.
|
| 204 |
Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.Oncol Rep. 2007 Jul;18(1):99-104.
|
| 205 |
Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer.Clin Biochem. 2008 Oct;41(14-15):1140-9. doi: 10.1016/j.clinbiochem.2008.04.026. Epub 2008 Jun 10.
|
| 206 |
REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase.Oncogene. 2005 Feb 10;24(7):1138-49. doi: 10.1038/sj.onc.1208236.
|
| 207 |
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.Cancer Res. 2008 Sep 15;68(18):7629-37. doi: 10.1158/0008-5472.CAN-08-2014.
|
| 208 |
DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130.Sci Rep. 2019 Feb 28;9(1):3035. doi: 10.1038/s41598-019-39537-z.
|
| 209 |
Assessment of the need for DCE MRI in the detection of dominant lesions in the whole gland: Correlation between histology and MRI of prostate cancer.NMR Biomed. 2018 Mar;31(3). doi: 10.1002/nbm.3882. Epub 2017 Dec 20.
|
| 210 |
Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential.J Mol Signal. 2007 Aug 24;2:7. doi: 10.1186/1750-2187-2-7.
|
| 211 |
Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1.Oncogene. 2018 Sep;37(39):5305-5324. doi: 10.1038/s41388-018-0294-0. Epub 2018 Jun 1.
|
| 212 |
High intracellular Zn2+ ions modulate the VHR, ZAP-70 and ERK activities of LNCaP prostate cancer cells.Cell Mol Biol Lett. 2008;13(3):375-90. doi: 10.2478/s11658-008-0009-6. Epub 2008 Feb 29.
|
| 213 |
E2F1 renders prostate cancer cell resistant to ICAM-1 mediated antitumor immunity by NF-B modulation.Mol Cancer. 2014 Apr 17;13:84. doi: 10.1186/1476-4598-13-84.
|
| 214 |
The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells.Prostate. 2012 May 1;72(6):649-60. doi: 10.1002/pros.21468. Epub 2011 Aug 11.
|
| 215 |
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
|
| 216 |
Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun. 2009 Feb 13;379(3):726-31. doi: 10.1016/j.bbrc.2008.12.098. Epub 2008 Dec 29.
|
| 217 |
Synthesis and pharmacological evaluation of novel epidermal growth factor receptor inhibitors against prostate tumor cells.Oncol Lett. 2018 Nov;16(5):6522-6530. doi: 10.3892/ol.2018.9438. Epub 2018 Sep 14.
|
| 218 |
PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability.Oncotarget. 2015 Aug 21;6(24):20356-69. doi: 10.18632/oncotarget.3931.
|
| 219 |
Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression.Cell Death Dis. 2017 Oct 12;8(10):e3122. doi: 10.1038/cddis.2017.507.
|
| 220 |
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.Cell Death Dis. 2019 Oct 22;10(11):801. doi: 10.1038/s41419-019-2042-y.
|
| 221 |
Association between estrogen and androgen receptor genes and prostate cancer risk.Eur J Endocrinol. 2009 Jan;160(1):101-6. doi: 10.1530/EJE-08-0321. Epub 2008 Oct 24.
|
| 222 |
The orphan receptor ERRalpha interferes with steroid signaling.Nucleic Acids Res. 2008 Sep;36(16):5350-61. doi: 10.1093/nar/gkn520. Epub 2008 Aug 12.
|
| 223 |
Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer.Oncogene. 2008 May 22;27(23):3313-28. doi: 10.1038/sj.onc.1210986. Epub 2007 Dec 10.
|
| 224 |
ETS1 induces transforming growth factor signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.J Cell Biochem. 2019 Jan;120(1):848-860. doi: 10.1002/jcb.27446. Epub 2018 Aug 30.
|
| 225 |
Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice.J Thromb Haemost. 2018 Nov;16(11):2258-2269. doi: 10.1111/jth.14277. Epub 2018 Sep 27.
|
| 226 |
Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression.J Biol Chem. 2008 May 2;283(18):12293-304. doi: 10.1074/jbc.M709493200. Epub 2008 Feb 28.
|
| 227 |
Loss of Par3 promotes prostatic tumorigenesis by enhancing cell growth and changing cell division modes.Oncogene. 2019 Mar;38(12):2192-2205. doi: 10.1038/s41388-018-0580-x. Epub 2018 Nov 22.
|
| 228 |
Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer.Prostate. 2007 May 15;67(7):743-56. doi: 10.1002/pros.20503.
|
| 229 |
Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression.Int J Oncol. 2008 Apr;32(4):767-75.
|
| 230 |
Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation. J Biol Chem. 2007 Jun 29;282(26):18777-85. doi: 10.1074/jbc.M611763200. Epub 2007 May 5.
|
| 231 |
The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.Mol Cancer Res. 2009 Jan;7(1):142-55. doi: 10.1158/1541-7786.MCR-08-0117.
|
| 232 |
Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells.Prostate. 2004 Nov 1;61(3):236-42. doi: 10.1002/pros.20093.
|
| 233 |
FGF-8 is involved in bone metastasis of prostate cancer.Int J Cancer. 2008 Jul 1;123(1):22-31. doi: 10.1002/ijc.23422.
|
| 234 |
Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2.Cancer Res. 1998 Apr 1;58(7):1509-14.
|
| 235 |
Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.Int J Cancer. 2008 Dec 1;123(11):2574-9. doi: 10.1002/ijc.23578.
|
| 236 |
Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2).J Thromb Haemost. 2008 Jan;6(1):176-83. doi: 10.1111/j.1538-7836.2007.02808.x. Epub 2007 Oct 22.
|
| 237 |
Strong signature of natural selection within an FHIT intron implicated in prostate cancer risk.PLoS One. 2008;3(10):e3533. doi: 10.1371/journal.pone.0003533. Epub 2008 Oct 27.
|
| 238 |
Identification and validation of novel androgen-regulated genes in prostate cancer.Endocrinology. 2004 Aug;145(8):3913-24. doi: 10.1210/en.2004-0311. Epub 2004 May 6.
|
| 239 |
Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis.Prostate. 2005 Oct 1;65(2):110-6. doi: 10.1002/pros.20276.
|
| 240 |
Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.Cancer Res. 1999 Nov 1;59(21):5565-71.
|
| 241 |
Gene transfer of alpha1,3-fucosyltransferase increases tumor growth of the PC-3 human prostate cancer cell line through enhanced adhesion to prostatic stromal cells.Int J Cancer. 2003 Dec 20;107(6):949-57. doi: 10.1002/ijc.11513.
|
| 242 |
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila). 2010 Sep;3(9):1084-92.
|
| 243 |
An androgen receptor gene mutation (A645D) in a boy with a normal phenotype.Hum Mutat. 1998;11(4):339.
|
| 244 |
Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis. J Cell Physiol. 2014 Mar;229(3):362-73. doi: 10.1002/jcp.24458.
|
| 245 |
RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer.Cancer Res. 2004 Feb 1;64(3):969-76. doi: 10.1158/0008-5472.can-03-2592.
|
| 246 |
Alteration of glyoxalase genes expression in response to testosterone in LNCaP and PC3 human prostate cancer cells.Cancer Biol Ther. 2007 Dec;6(12):1880-8. doi: 10.4161/cbt.6.12.4961. Epub 2007 Sep 1.
|
| 247 |
The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary.Mol Cell Endocrinol. 1994 Dec;106(1-2):145-9. doi: 10.1016/0303-7207(94)90196-1.
|
| 248 |
Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.
|
| 249 |
Targeting Gbetagamma signaling to inhibit prostate tumor formation and growth.J Biol Chem. 2003 Sep 26;278(39):37569-73. doi: 10.1074/jbc.M306276200. Epub 2003 Jul 17.
|
| 250 |
GRK3 is essential for metastatic cells and promotes prostate tumor progression.Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1521-6. doi: 10.1073/pnas.1320638111. Epub 2014 Jan 13.
|
| 251 |
Glycogen synthase kinase 3 regulates cell death and survival signaling in tumor cells under redox stress. Neoplasia. 2014 Sep;16(9):710-22.
|
| 252 |
NF-B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.Mol Cancer Ther. 2015 Aug;14(8):1884-95. doi: 10.1158/1535-7163.MCT-14-1057. Epub 2015 Jun 8.
|
| 253 |
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.Nature. 2007 Aug 2;448(7153):595-9. doi: 10.1038/nature06024.
|
| 254 |
Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies.Oncotarget. 2017 Nov 6;8(62):104761-104771. doi: 10.18632/oncotarget.22289. eCollection 2017 Dec 1.
|
| 255 |
Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.Proteomics. 2007 Jun;7(12):1973-83. doi: 10.1002/pmic.200600643.
|
| 256 |
Transcriptional activation by NFB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment.J Cell Biochem. 2014 Jul;115(7):1322-33. doi: 10.1002/jcb.24788.
|
| 257 |
TIP30 is associated with progression and metastasis of prostate cancer.Int J Cancer. 2008 Aug 15;123(4):810-6. doi: 10.1002/ijc.23638.
|
| 258 |
Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression.Clin Cancer Res. 2004 Mar 15;10(6):2044-51. doi: 10.1158/1078-0432.ccr-03-0933.
|
| 259 |
IFNL4-G Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer.Clin Cancer Res. 2018 Nov 1;24(21):5471-5481. doi: 10.1158/1078-0432.CCR-18-1060. Epub 2018 Jul 16.
|
| 260 |
Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model.Oncogene. 2019 Sep;38(36):6338-6353. doi: 10.1038/s41388-019-0880-9. Epub 2019 Jul 16.
|
| 261 |
Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival.Endocrinology. 2003 Jun;144(6):2319-24. doi: 10.1210/en.2003-221028.
|
| 262 |
PAPA-1 Is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions.Mol Endocrinol. 2009 Feb;23(2):169-75. doi: 10.1210/me.2008-0168. Epub 2008 Dec 18.
|
| 263 |
Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression.Prostate. 2007 Nov 1;67(15):1621-9. doi: 10.1002/pros.20655.
|
| 264 |
Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer. Br J Cancer. 2005 Apr 25;92(8):1538-44. doi: 10.1038/sj.bjc.6602520.
|
| 265 |
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer.Cancer Res. 2004 Jan 15;64(2):435-9. doi: 10.1158/0008-5472.can-03-2675.
|
| 266 |
Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy.Cancer Res. 2008 Nov 15;68(22):9311-7. doi: 10.1158/0008-5472.CAN-08-2810.
|
| 267 |
Multiple loci identified in a genome-wide association study of prostate cancer.Nat Genet. 2008 Mar;40(3):310-5. doi: 10.1038/ng.91. Epub 2008 Feb 10.
|
| 268 |
Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro.J Cell Physiol. 2013 May;228(5):1127-36. doi: 10.1002/jcp.24265.
|
| 269 |
Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):480-5. doi: 10.1158/1055-9965.EPI-05-0645.
|
| 270 |
Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis.J Cell Biochem. 2018 Nov;119(10):8074-8083. doi: 10.1002/jcb.26727. Epub 2018 Jun 22.
|
| 271 |
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.Nature. 2014 Nov 6;515(7525):134-7. doi: 10.1038/nature13638. Epub 2014 Aug 24.
|
| 272 |
Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells.Mol Imaging. 2008 Sep-Oct;7(5):199-213.
|
| 273 |
Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells.Int J Cancer. 2009 Apr 15;124(8):1980-9. doi: 10.1002/ijc.24139.
|
| 274 |
KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer.Oncogene. 2007 Apr 12;26(17):2525-34. doi: 10.1038/sj.onc.1210036. Epub 2006 Dec 4.
|
| 275 |
Klotho inhibits androgen/androgen receptorassociated epithelialmesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.Oncol Rep. 2018 Jul;40(1):217-225. doi: 10.3892/or.2018.6399. Epub 2018 Apr 25.
|
| 276 |
The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.Mol Oncol. 2020 Jan;14(1):105-128. doi: 10.1002/1878-0261.12587. Epub 2019 Nov 28.
|
| 277 |
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.Int J Cancer. 2009 Feb 1;124(3):659-63. doi: 10.1002/ijc.23983.
|
| 278 |
Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.Thromb Haemost. 2009 Feb;101(2):373-80.
|
| 279 |
Inhibition of Karyopherin beta 1 suppresses prostate cancer growth.Oncogene. 2019 Jun;38(24):4700-4714. doi: 10.1038/s41388-019-0745-2. Epub 2019 Feb 11.
|
| 280 |
Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men.Prostate Cancer Prostatic Dis. 2008;11(3):264-9. doi: 10.1038/sj.pcan.4501022. Epub 2007 Oct 16.
|
| 281 |
LIM kinase1 modulates function of membrane type matrix metalloproteinase 1: implication in invasion of prostate cancer cells.Mol Cancer. 2011 Jan 10;10:6. doi: 10.1186/1476-4598-10-6.
|
| 282 |
Overexpression of the oncogenic kinase Pim-1 leads to genomic instability.Cancer Res. 2003 Dec 1;63(23):8079-84.
|
| 283 |
Down-regulation of Lsm1 is involved in human prostate cancer progression.Br J Cancer. 2002 Mar 18;86(6):940-6. doi: 10.1038/sj.bjc.6600163.
|
| 284 |
Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.Prostate. 2006 Jan 1;66(1):13-8. doi: 10.1002/pros.20312.
|
| 285 |
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.Oncogene. 2003 Mar 6;22(9):1381-9. doi: 10.1038/sj.onc.1206154.
|
| 286 |
TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma).Histopathology. 2008 Aug;53(2):166-76. doi: 10.1111/j.1365-2559.2008.03092.x.
|
| 287 |
Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma.Anal Cell Pathol. 2000;21(1):1-9. doi: 10.1155/2000/351963.
|
| 288 |
Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.J Exp Clin Cancer Res. 2017 Aug 23;36(1):112. doi: 10.1186/s13046-017-0583-4.
|
| 289 |
JNK interacting protein 1 (JIP-1) protects LNCaP prostate cancer cells from growth arrest and apoptosis mediated by 12-0-tetradecanoylphorbol-13-acetate (TPA).Br J Cancer. 2004 May 17;90(10):2017-24. doi: 10.1038/sj.bjc.6601834.
|
| 290 |
MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer.Oncogene. 2006 May 18;25(21):2987-98. doi: 10.1038/sj.onc.1209337.
|
| 291 |
Carboxyl-terminal repressor domain of MBP-1 is sufficient for regression of prostate tumor growth in nude mice.Cancer Res. 2005 Feb 1;65(3):718-21.
|
| 292 |
CD146 protein in prostate cancer: revisited with two different antibodies.Pathology. 2008 Aug;40(5):457-64. doi: 10.1080/00313020802197996.
|
| 293 |
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.Cancer Res. 2008 Aug 1;68(15):6162-70. doi: 10.1158/0008-5472.CAN-08-0144.
|
| 294 |
Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.J Pharmacol Exp Ther. 2011 Jul;338(1):173-83. doi: 10.1124/jpet.111.180364. Epub 2011 Mar 28.
|
| 295 |
Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.Clin Invest Med. 2008;31(1):E8-E15. doi: 10.25011/cim.v31i1.3136.
|
| 296 |
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.Clin Cancer Res. 2008 Dec 1;14(23):7838-42. doi: 10.1158/1078-0432.CCR-08-1432.
|
| 297 |
Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts.Actas Urol Esp. 2017 Jul-Aug;41(6):376-382. doi: 10.1016/j.acuro.2016.12.001. Epub 2017 Feb 1.
|
| 298 |
Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.Prostate. 2018 Mar;78(4):257-265. doi: 10.1002/pros.23466. Epub 2017 Dec 18.
|
| 299 |
MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.Carcinogenesis. 2007 Dec;28(12):2530-6. doi: 10.1093/carcin/bgm196. Epub 2007 Sep 3.
|
| 300 |
The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.Oncogene. 2011 Dec 15;30(50):4990-8. doi: 10.1038/onc.2011.205. Epub 2011 May 30.
|
| 301 |
Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1.Br J Cancer. 2018 Feb 20;118(4):587-599. doi: 10.1038/bjc.2017.431. Epub 2018 Feb 20.
|
| 302 |
MYH mutations are rare in prostate cancer.J Cancer Res Clin Oncol. 2007 Jun;133(6):373-8. doi: 10.1007/s00432-006-0181-x. Epub 2007 Jan 12.
|
| 303 |
Expression and secretion of N-acylethanolamine-hydrolysing acid amidase in human prostate cancer cells.J Biochem. 2008 Nov;144(5):685-90. doi: 10.1093/jb/mvn122. Epub 2008 Sep 19.
|
| 304 |
Androgen receptor coactivator ARA70alpha and ARA70beta isoform-specific antibodies: new tools for studies of expression and immunohistochemical localization.Appl Immunohistochem Mol Morphol. 2008 Jan;16(1):7-12. doi: 10.1097/PAI.0b013e31802e91ea.
|
| 305 |
Plasmid-based Survivin shRNA and GRIM-19 carried by attenuated Salmonella suppresses tumor cell growth.Asian J Androl. 2012 Jul;14(4):536-45. doi: 10.1038/aja.2011.179. Epub 2012 May 14.
|
| 306 |
A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells.J Biol Chem. 2008 Oct 24;283(43):28988-95. doi: 10.1074/jbc.M710528200. Epub 2008 Aug 14.
|
| 307 |
Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.Int J Cancer. 2019 Aug 15;145(4):1055-1067. doi: 10.1002/ijc.32200. Epub 2019 Feb 25.
|
| 308 |
The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
|
| 309 |
Targeted induction of endogenous NKX3-1 by small activating RNA inhibits prostate tumor growth.Prostate. 2013 Oct;73(14):1591-601. doi: 10.1002/pros.22709. Epub 2013 Jul 8.
|
| 310 |
NPM1 silencing reduces tumour growth and MAPK signalling in prostate cancer cells.PLoS One. 2014 May 5;9(5):e96293. doi: 10.1371/journal.pone.0096293. eCollection 2014.
|
| 311 |
C-type natriuretic peptide in prostate cancer.APMIS. 2009 Jan;117(1):60-7. doi: 10.1111/j.1600-0463.2008.00016.x.
|
| 312 |
Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.J Zhejiang Univ Sci B. 2007 Dec;8(12):853-9. doi: 10.1631/jzus.2007.B0853.
|
| 313 |
Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells.Endocrinology. 2006 Mar;147(3):1466-73. doi: 10.1210/en.2005-0925. Epub 2005 Dec 8.
|
| 314 |
The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.Biochem Biophys Res Commun. 2007 Jun 1;357(2):341-6. doi: 10.1016/j.bbrc.2007.03.116. Epub 2007 Mar 28.
|
| 315 |
Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer.Clin Cancer Res. 2007 Jun 1;13(11):3147-55. doi: 10.1158/1078-0432.CCR-06-2237.
|
| 316 |
VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.Cancer Discov. 2012 Oct;2(10):906-21. doi: 10.1158/2159-8290.CD-12-0085. Epub 2012 Jul 9.
|
| 317 |
Characterization of nerve growth factor precursor protein expression by human prostate stromal cells: a role in selective neurotrophin stimulation of prostate epithelial cell growth.Prostate. 1999 Sep 15;41(1):39-48. doi: 10.1002/(sici)1097-0045(19990915)41:1<39::aid-pros6>3.0.co;2-e.
|
| 318 |
A novel function of differentiation revealed by cDNA microarray profiling of p75NTR-regulated gene expression.Differentiation. 2005 Oct;73(8):385-96. doi: 10.1111/j.1432-0436.2005.00040.x.
|
| 319 |
Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress.Regul Pept. 2007 Jun 7;141(1-3):140-53. doi: 10.1016/j.regpep.2006.12.027. Epub 2007 Jan 16.
|
| 320 |
Resolution of genotypic heterogeneity in prostate tumors using polymerase chain reaction and comparative genomic hybridization on microdissected carcinoma and prostatic intraepithelial neoplasia foci.Cancer Genet Cytogenet. 2002 Aug;137(1):15-22. doi: 10.1016/s0165-4608(02)00540-x.
|
| 321 |
Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression.Oncogene. 2016 Mar 3;35(9):1153-62. doi: 10.1038/onc.2015.170. Epub 2015 Jun 1.
|
| 322 |
Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival.Biochem Biophys Res Commun. 2006 Jan 6;339(1):93-8. doi: 10.1016/j.bbrc.2005.10.189. Epub 2005 Nov 8.
|
| 323 |
The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression.Oncotarget. 2014 Aug 30;5(16):6654-69. doi: 10.18632/oncotarget.2208.
|
| 324 |
P21 activated kinase-1 mediates transforming growth factor 1-induced prostate cancer cell epithelial to mesenchymal transition.Biochim Biophys Acta. 2015 May;1853(5):1229-39. doi: 10.1016/j.bbamcr.2015.02.023. Epub 2015 Mar 6.
|
| 325 |
Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK.J Biol Chem. 2005 Jul 15;280(28):26278-86. doi: 10.1074/jbc.M414467200. Epub 2005 May 20.
|
| 326 |
Tumour-suppression activity of the proapoptotic regulator Par4.EMBO Rep. 2005 Jun;6(6):577-83. doi: 10.1038/sj.embor.7400421.
|
| 327 |
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.Stem Cells. 2008 Jun;26(6):1425-35. doi: 10.1634/stemcells.2007-1076. Epub 2008 Apr 10.
|
| 328 |
A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.Prostate. 2007 Nov 1;67(15):1664-76. doi: 10.1002/pros.20657.
|
| 329 |
Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue.APMIS. 2008 Jun;116(6):491-8. doi: 10.1111/j.1600-0463.2008.01020.x.
|
| 330 |
Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens.Oncogene. 2012 Oct 25;31(43):4588-98. doi: 10.1038/onc.2011.591. Epub 2011 Dec 19.
|
| 331 |
Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.Prostate. 2018 Sep;78(13):1013-1023. doi: 10.1002/pros.23659. Epub 2018 May 29.
|
| 332 |
Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer.Prostate. 2005 Nov 1;65(3):276-86. doi: 10.1002/pros.20294.
|
| 333 |
Small Molecule Pin1 Inhibitor Blocking NF-B Signaling in Prostate Cancer Cells.Chem Asian J. 2018 Feb 2;13(3):275-279. doi: 10.1002/asia.201701216. Epub 2018 Jan 15.
|
| 334 |
A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer.EMBO J. 2003 Jan 15;22(2):270-80. doi: 10.1093/emboj/cdg023.
|
| 335 |
Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.BJU Int. 2006 Feb;97(2):404-9. doi: 10.1111/j.1464-410X.2005.05912.x.
|
| 336 |
suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.Int J Oncol. 2008 Jan;32(1):185-91. doi: 10.3892/ijo.32.1.185.
|
| 337 |
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.Mol Cancer Ther. 2017 Mar;16(3):469-479. doi: 10.1158/1535-7163.MCT-16-0361. Epub 2017 Jan 9.
|
| 338 |
Transcription-targeted gene therapy for androgen-independent prostate cancer.Cancer Gene Ther. 2002 May;9(5):443-52. doi: 10.1038/sj.cgt.7700451.
|
| 339 |
PGC1 Suppresses Prostate Cancer Cell Invasion through ERR Transcriptional Control.Cancer Res. 2019 Dec 15;79(24):6153-6165. doi: 10.1158/0008-5472.CAN-19-1231. Epub 2019 Oct 8.
|
| 340 |
Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene. 2006 Nov 23;25(55):7311-23.
|
| 341 |
PCPH/ENTPD5 expression enhances the invasiveness of human prostate cancer cells by a protein kinase C delta-dependent mechanism.Cancer Res. 2007 Nov 15;67(22):10859-68. doi: 10.1158/0008-5472.CAN-07-2041.
|
| 342 |
Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells.Oncogene. 2004 Nov 11;23(53):8659-72. doi: 10.1038/sj.onc.1207900.
|
| 343 |
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.Prostate. 2005 Jun 15;64(1):29-39. doi: 10.1002/pros.20236.
|
| 344 |
Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG. Prostate. 2006 Jun 15;66(9):911-20. doi: 10.1002/pros.20325.
|
| 345 |
The application of prostate specific membrane antigen in CARTcell therapy for treatment of prostate carcinoma (Review).Oncol Rep. 2018 Dec;40(6):3136-3143. doi: 10.3892/or.2018.6758. Epub 2018 Oct 1.
|
| 346 |
Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer.Neoplasma. 2017;64(5):732-737. doi: 10.4149/neo_2017_511.
|
| 347 |
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.Cancer Res. 2008 Oct 1;68(19):7750-9. doi: 10.1158/0008-5472.CAN-07-6689.
|
| 348 |
Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.J Cell Physiol. 2008 Sep;216(3):780-9. doi: 10.1002/jcp.21460.
|
| 349 |
RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer.Cancer Res. 2008 Sep 15;68(18):7613-20. doi: 10.1158/0008-5472.CAN-07-6700.
|
| 350 |
Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells.J Biol Chem. 2006 Oct 27;281(43):32217-26. doi: 10.1074/jbc.M607104200. Epub 2006 Aug 29.
|
| 351 |
PRL? increases the aggressive phenotype of prostate cancer cells invitro and its expression correlates with high-grade prostate tumors in patients.Int J Oncol. 2018 Feb;52(2):402-412. doi: 10.3892/ijo.2017.4208. Epub 2017 Nov 20.
|
| 352 |
PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.Cancer Res. 2012 Mar 15;72(6):1529-37. doi: 10.1158/0008-5472.CAN-11-2602. Epub 2012 Jan 26.
|
| 353 |
Synergistic chromatin repression of the tumor suppressor gene RARB in human prostate cancers.Epigenetics. 2014 Apr;9(4):477-82. doi: 10.4161/epi.27869. Epub 2014 Feb 3.
|
| 354 |
Re: Anja Rabien, Mick Burkhardt, Monika Jung, Florian Fritzsche, Martin Ringsdorf, Hanka Schicktanz, Stefan A. Loening, Glen Kristiansen and Klaus Jung. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Eur Urol 2007;51:1259-66.Eur Urol. 2007 Nov;52(5):1533-4; author reply 1534-5. doi: 10.1016/j.eururo.2007.06.004. Epub 2007 Jun 12.
|
| 355 |
Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.Oncogene. 2006 Jun 22;25(26):3719-34. doi: 10.1038/sj.onc.1209408. Epub 2006 Jan 30.
|
| 356 |
Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells.Exp Cell Res. 2008 Oct 15;314(17):3162-74. doi: 10.1016/j.yexcr.2008.07.012. Epub 2008 Jul 25.
|
| 357 |
MicroRNA?22 downregulates Rhoassociated protein kinase 2 expression and inhibits the proliferation of prostate carcinoma cells.Mol Med Rep. 2019 May;19(5):3882-3888. doi: 10.3892/mmr.2019.9995. Epub 2019 Feb 27.
|
| 358 |
The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.Cancer Res. 2005 Apr 15;65(8):3108-16. doi: 10.1158/0008-5472.CAN-04-3151.
|
| 359 |
Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation.Cancer Lett. 2018 Oct 1;433:232-241. doi: 10.1016/j.canlet.2018.07.009. Epub 2018 Jul 9.
|
| 360 |
Cell fate regulation by reticulon-4 in human prostate cancers.J Cell Physiol. 2019 Jul;234(7):10372-10385. doi: 10.1002/jcp.27704. Epub 2018 Nov 27.
|
| 361 |
Nitric Oxide Up-Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In Vivo.J Cell Physiol. 2016 Feb;231(2):473-82. doi: 10.1002/jcp.25093.
|
| 362 |
Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-alpha.Endocrinology. 2008 Apr;149(4):1802-12. doi: 10.1210/en.2007-1315. Epub 2007 Dec 27.
|
| 363 |
Immunohistochemical detection of the retinoid X receptors alpha, beta, and gamma in human prostate.J Androl. 2003 Jan-Feb;24(1):113-9.
|
| 364 |
Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel.Mol Cancer. 2007 Nov 24;6:76. doi: 10.1186/1476-4598-6-76.
|
| 365 |
Role of desumoylation in the development of prostate cancer.Neoplasia. 2006 Aug;8(8):667-76. doi: 10.1593/neo.06445.
|
| 366 |
Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT.Oncogene. 2008 Dec 4;27(57):7171-9. doi: 10.1038/onc.2008.321. Epub 2008 Oct 20.
|
| 367 |
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.Am J Pathol. 2002 Dec;161(6):2053-63. doi: 10.1016/S0002-9440(10)64484-7.
|
| 368 |
Vacuolar H+-ATPase is down-regulated by the angiogenesis-inhibitory pigment epithelium-derived factor in metastatic prostate cancer cells.Cell Mol Biol (Noisy-le-grand). 2014 May 25;60(1):45-52.
|
| 369 |
TET2 binds the androgen receptor and loss is associated with prostate cancer.Oncogene. 2017 Apr;36(15):2172-2183. doi: 10.1038/onc.2016.376. Epub 2016 Nov 7.
|
| 370 |
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.J Cell Physiol. 2005 Mar;202(3):654-62. doi: 10.1002/jcp.20166.
|
| 371 |
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1655-60. doi: 10.1073/pnas.0610291104. Epub 2007 Jan 18.
|
| 372 |
Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas.J Neurooncol. 2018 Jul;138(3):557-569. doi: 10.1007/s11060-018-2823-7. Epub 2018 Mar 10.
|
| 373 |
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.BJU Int. 2008 Aug 5;102(5):617-21. doi: 10.1111/j.1464-410X.2008.07629.x. Epub 2008 Jun 4.
|
| 374 |
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.Oncogene. 2010 Sep 30;29(39):5370-80. doi: 10.1038/onc.2010.269. Epub 2010 Jul 12.
|
| 375 |
BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer.J Cell Physiol. 2019 Sep;234(9):15194-15205. doi: 10.1002/jcp.28161. Epub 2019 Jan 22.
|
| 376 |
SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.J Natl Cancer Inst. 2013 Nov 20;105(22):1719-28. doi: 10.1093/jnci/djt304. Epub 2013 Oct 30.
|
| 377 |
The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis. Med Oncol. 2015 Nov;32(11):251.
|
| 378 |
DNA fingerprinting tags novel altered chromosomal regions and identifies the involvement of SOX5 in the progression of prostate cancer.Int J Cancer. 2009 May 15;124(10):2323-32. doi: 10.1002/ijc.24243.
|
| 379 |
SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.PLoS Genet. 2014 Sep 25;10(9):e1004656. doi: 10.1371/journal.pgen.1004656. eCollection 2014 Sep.
|
| 380 |
Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression.Tumour Biol. 2015 Dec;36(12):9567-77. doi: 10.1007/s13277-015-3628-3. Epub 2015 Jul 4.
|
| 381 |
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
|
| 382 |
KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.Biochem J. 2009 Jan 1;417(1):313-22. doi: 10.1042/BJ20080762.
|
| 383 |
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.Cancer Res. 2004 Mar 15;64(6):2212-21. doi: 10.1158/0008-5472.can-2148-2.
|
| 384 |
Identification of prognostic biomarkers for prostate cancer.Clin Cancer Res. 2008 Mar 15;14(6):1734-43. doi: 10.1158/1078-0432.CCR-07-1494.
|
| 385 |
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.Prostate. 2002 Sep 15;53(1):50-9. doi: 10.1002/pros.10121.
|
| 386 |
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines.Urol Oncol. 2002 May-Jun;7(3):91-8. doi: 10.1016/s1078-1439(01)00173-9.
|
| 387 |
Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer.Oncogene. 2005 Jul 21;24(31):4934-45. doi: 10.1038/sj.onc.1208677.
|
| 388 |
Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth.Mol Endocrinol. 2007 Feb;21(2):343-58. doi: 10.1210/me.2006-0104. Epub 2006 Nov 2.
|
| 389 |
Thromboxane A2 receptors in prostate carcinoma: expression and its role in regulating cell motility via small GTPase Rho.Cancer Res. 2008 Jan 1;68(1):115-21. doi: 10.1158/0008-5472.CAN-07-1018.
|
| 390 |
Frequency of TERT Promoter Mutations in Prostate Cancer.Pathobiology. 2015;82(2):53-7. doi: 10.1159/000381903. Epub 2015 May 21.
|
| 391 |
TGF signaling limits lineage plasticity in prostate cancer.PLoS Genet. 2018 May 21;14(5):e1007409. doi: 10.1371/journal.pgen.1007409. eCollection 2018 May.
|
| 392 |
Prognostic relevance of Tiam1 protein expression in prostate carcinomas.Br J Cancer. 2006 Oct 23;95(8):1081-6. doi: 10.1038/sj.bjc.6603385. Epub 2006 Sep 26.
|
| 393 |
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.Clin Cancer Res. 2007 Dec 1;13(23):6947-58. doi: 10.1158/1078-0432.CCR-07-0842.
|
| 394 |
Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carc... Am J Pathol. 2003 Aug;163(2):543-52.
|
| 395 |
Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells. J Androl. 2008 Mar-Apr;29(2):207-12. doi: 10.2164/jandrol.107.003608. Epub 2007 Oct 3.
|
| 396 |
Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene. 2001 Nov 29;20(55):7965-75. doi: 10.1038/sj.onc.1204985.
|
| 397 |
Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.PLoS One. 2010 Dec 28;5(12):e15627. doi: 10.1371/journal.pone.0015627.
|
| 398 |
Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.Cell Res. 2008 Aug;18(8):858-70. doi: 10.1038/cr.2008.84.
|
| 399 |
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43. doi: 10.1073/pnas.0700420104. Epub 2007 May 9.
|
| 400 |
Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death.Cancer Res. 2007 Dec 15;67(24):11848-58. doi: 10.1158/0008-5472.CAN-07-1615.
|
| 401 |
P202, an interferon-inducible protein, inhibits E2F1-mediated apoptosis in prostate cancer cells.Biochem Biophys Res Commun. 2003 Mar 28;303(1):219-22. doi: 10.1016/s0006-291x(03)00320-6.
|
| 402 |
A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.Exp Cell Res. 1996 Jan 10;222(1):54-60. doi: 10.1006/excr.1996.0007.
|
| 403 |
Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.Cancer Res. 2010 Feb 1;70(3):1225-35. doi: 10.1158/0008-5472.CAN-09-2205. Epub 2010 Jan 26.
|
| 404 |
TRPV6.Handb Exp Pharmacol. 2007;(179):221-34. doi: 10.1007/978-3-540-34891-7_13.
|
| 405 |
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer.Cancer Cell. 2004 Mar;5(3):253-61. doi: 10.1016/s1535-6108(04)00055-8.
|
| 406 |
Interleukin-6 induced overexpression of valosin-containing protein (VCP)/p97 is associated with androgen-independent prostate cancer (AIPC) progression. J Cell Physiol. 2018 Oct;233(10):7148-7164. doi: 10.1002/jcp.26639. Epub 2018 Apr 25.
|
| 407 |
Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.Anal Quant Cytol Histol. 2008 Aug;30(4):199-202.
|
| 408 |
Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93.
|
| 409 |
Serum undercarboxylated osteocalcin as biomarker of vitamin K intake and risk of prostate cancer: a nested case-control study in the Heidelberg cohort of the European prospective investigation into cancer and nutrition.Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):49-56. doi: 10.1158/1055-9965.EPI-08-0554.
|
| 410 |
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27.
|
| 411 |
The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels.BJU Int. 2008 Feb;101(4):492-6. doi: 10.1111/j.1464-410X.2007.07272.x. Epub 2007 Nov 6.
|
| 412 |
EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.Mol Cancer Ther. 2008 Oct;7(10):3176-86. doi: 10.1158/1535-7163.MCT-08-0526.
|
| 413 |
SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.Oncotarget. 2015 Jan 20;6(2):771-88. doi: 10.18632/oncotarget.2718.
|
| 414 |
Membranous type matrix metalloproteinase 16 induces human prostate cancer metastasis.Oncol Lett. 2017 Sep;14(3):3096-3102. doi: 10.3892/ol.2017.6536. Epub 2017 Jul 7.
|
| 415 |
Silencing of GSTP1, a prostate cancer prognostic gene, by the estrogen receptor- and endothelial nitric oxide synthase complex.Mol Endocrinol. 2011 Dec;25(12):2003-16. doi: 10.1210/me.2011-1024. Epub 2011 Nov 3.
|
| 416 |
Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts.Oncotarget. 2015 Jun 10;6(16):14318-28. doi: 10.18632/oncotarget.3960.
|
| 417 |
Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness.Urology. 2011 Oct;78(4):971.e1-9. doi: 10.1016/j.urology.2011.04.055. Epub 2011 Jul 29.
|
| 418 |
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.Oncogene. 2003 Sep 4;22(38):6005-12. doi: 10.1038/sj.onc.1206797.
|
| 419 |
The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer.Cancer Res. 2005 Sep 15;65(18):8118-24. doi: 10.1158/0008-5472.CAN-04-4562.
|
| 420 |
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians.Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1257-61. doi: 10.1158/1055-9965.EPI-04-0534.
|
| 421 |
Heterocyclic aromatic amine [HCA] intake and prostate cancer risk: effect modification by genetic variants. Nutr Cancer. 2012;64(5):704-13. doi: 10.1080/01635581.2012.678548. Epub 2012 May 7.
|
| 422 |
Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men.Prostate. 2002 Sep 15;53(1):65-8. doi: 10.1002/pros.10134.
|
| 423 |
SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.Prostate. 2007 Nov 1;67(15):1654-63. doi: 10.1002/pros.20625.
|
| 424 |
Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells.Oncol Rep. 2007 Nov;18(5):1145-53.
|
| 425 |
Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population.Prostate. 2005 Aug 1;64(3):246-52. doi: 10.1002/pros.20241.
|
| 426 |
Further evidence for null association of phenol sulfotransferase SULT1A1 polymorphism with prostate cancer risk: a case-control study of familial prostate cancer in a Japanese population.Int Urol Nephrol. 2008;40(4):947-51. doi: 10.1007/s11255-008-9364-5. Epub 2008 Mar 27.
|
| 427 |
Polymorphisms of GSTM1 and CYP1A1 genes and their genetic susceptibility to prostate cancer in Chinese men.Chin Med J (Engl). 2008 Feb 20;121(4):305-8.
|
| 428 |
Role of oncoprotein growth factor independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): a comparative analysis in human prostate cancer and kidney cells. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):742-6.
|
| 429 |
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Antimicrob Agents Chemother. 2000 Oct;44(10):2659-63.
|
| 430 |
Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.Prostate. 2007 Sep 15;67(13):1439-46. doi: 10.1002/pros.20630.
|
| 431 |
Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology. 2007 Aug;70(2):374-9.
|
| 432 |
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.Cancer Res. 2005 Jul 15;65(14):6189-98. doi: 10.1158/0008-5472.CAN-04-4439.
|
| 433 |
Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues.Prostate. 2008 May 15;68(7):766-72. doi: 10.1002/pros.20735.
|
| 434 |
Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.Cancer Sci. 2008 Jan;99(1):81-6. doi: 10.1111/j.1349-7006.2007.00656.x. Epub 2007 Nov 6.
|
| 435 |
Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.Mol Cancer Ther. 2008 Feb;7(2):380-90. doi: 10.1158/1535-7163.MCT-07-0455.
|
| 436 |
Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.J Pharmacol Exp Ther. 2017 Jun;361(3):482-491. doi: 10.1124/jpet.117.240317. Epub 2017 Apr 12.
|
| 437 |
Identification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray Analysis.Dis Markers. 2015;2015:241301. doi: 10.1155/2015/241301. Epub 2015 Sep 28.
|
| 438 |
Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines.Prostate. 2008 Feb 15;68(3):336-43. doi: 10.1002/pros.20707.
|
| 439 |
Copy number alterations in prostate tumors and disease aggressiveness.Genes Chromosomes Cancer. 2012 Jan;51(1):66-76. doi: 10.1002/gcc.20932. Epub 2011 Oct 2.
|
| 440 |
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.J Clin Oncol. 2013 May 10;31(14):1748-57. doi: 10.1200/JCO.2012.43.1882. Epub 2013 Apr 8.
|
| 441 |
Genetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progression.Sci Rep. 2017 Jul 3;7(1):4538. doi: 10.1038/s41598-017-04731-4.
|
| 442 |
Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
|
| 443 |
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.Nat Genet. 2009 Feb;41(2):221-7. doi: 10.1038/ng.296. Epub 2009 Jan 18.
|
| 444 |
The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.Oncogene. 2015 Jan 8;34(2):226-36. doi: 10.1038/onc.2013.538. Epub 2014 Jan 20.
|
| 445 |
DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.Epigenetics. 2016 Sep;11(9):674-689. doi: 10.1080/15592294.2016.1208891. Epub 2016 Jul 14.
|
| 446 |
CTBP1 depletion on prostate tumors deregulates miRNA/mRNA expression and impairs cancer progression in metabolic syndrome mice.Cell Death Dis. 2019 Apr 1;10(4):299. doi: 10.1038/s41419-019-1535-z.
|
| 447 |
A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.Genes Chromosomes Cancer. 1998 May;22(1):26-36.
|
| 448 |
Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.J Biol Chem. 2015 Jun 19;290(25):15406-15420. doi: 10.1074/jbc.M115.658765. Epub 2015 Apr 22.
|
| 449 |
DLEC1, a 3p tumor suppressor, represses NF-B signaling and is methylated in prostate cancer.J Mol Med (Berl). 2015 Jun;93(6):691-701. doi: 10.1007/s00109-015-1255-5. Epub 2015 Feb 5.
|
| 450 |
Downregulation of several fibulin genes in prostate cancer.Prostate. 2007 Dec 1;67(16):1770-80. doi: 10.1002/pros.20667.
|
| 451 |
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.Br J Cancer. 2004 Mar 8;90(5):1041-6. doi: 10.1038/sj.bjc.6601648.
|
| 452 |
Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.Carcinogenesis. 2008 May;29(5):999-1004. doi: 10.1093/carcin/bgn081. Epub 2008 Mar 28.
|
| 453 |
PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.Cancer Res. 2009 Jan 1;69(1):102-10. doi: 10.1158/0008-5472.CAN-08-2922.
|
| 454 |
Association of XPD polymorphisms with prostate cancer in Taiwanese patients.Anticancer Res. 2007 Jul-Aug;27(4C):2893-6.
|
| 455 |
PTX1(ERGIC2)-VP22 fusion protein upregulates interferon-beta in prostate cancer cell line PC-3.DNA Cell Biol. 2006 Sep;25(9):523-9. doi: 10.1089/dna.2006.25.523.
|
| 456 |
An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.Cell Rep. 2016 Oct 25;17(5):1289-1301. doi: 10.1016/j.celrep.2016.10.001.
|
| 457 |
Minireview: Role of genetic changes of faciogenital dysplasia protein 1 in human disease.Physiol Genomics. 2016 Jul 1;48(7):446-54. doi: 10.1152/physiolgenomics.00101.2015. Epub 2016 May 6.
|
| 458 |
Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population.Nat Genet. 2010 Sep;42(9):751-4. doi: 10.1038/ng.635. Epub 2010 Aug 1.
|
| 459 |
An A/G polymorphism of core 2 branching enzyme gene is associated with prostate cancer.Biochem Biophys Res Commun. 2005 Jun 17;331(4):958-63. doi: 10.1016/j.bbrc.2005.04.022.
|
| 460 |
The role of sarcosine metabolism in prostate cancer progression.Neoplasia. 2013 May;15(5):491-501. doi: 10.1593/neo.13314.
|
| 461 |
Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression.PLoS One. 2015 Feb 18;10(2):e0117758. doi: 10.1371/journal.pone.0117758. eCollection 2015.
|
| 462 |
Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis.Cancer Res. 2007 Sep 1;67(17):8043-50. doi: 10.1158/0008-5472.CAN-07-0648.
|
| 463 |
Metabolic susceptibility genes and prostate cancer risk in a southern European population: the role of glutathione S-transferases GSTM1, GSTM3, and GSTT1 genetic polymorphisms.Prostate. 2004 Mar 1;58(4):414-20. doi: 10.1002/pros.10348.
|
| 464 |
Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life.Endocrinology. 2012 Jan;153(1):42-55. doi: 10.1210/en.2011-1308. Epub 2011 Nov 22.
|
| 465 |
Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.Clin Cancer Res. 2016 Apr 1;22(7):1744-56. doi: 10.1158/1078-0432.CCR-15-1606. Epub 2015 Nov 9.
|
| 466 |
The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer.Int J Hyperthermia. 2004 Dec;20(8):835-49. doi: 10.1080/02656730410001721807.
|
| 467 |
Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling.Cancer Res. 2010 Nov 15;70(22):9106-17. doi: 10.1158/0008-5472.CAN-10-1119. Epub 2010 Nov 9.
|
| 468 |
Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancers.Neoplasia. 2007 Jun;9(6):464-70. doi: 10.1593/neo.07109.
|
| 469 |
Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer.Oncogene. 2006 Jul 6;25(29):4122-7. doi: 10.1038/sj.onc.1209428. Epub 2006 Feb 13.
|
| 470 |
Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma.J Natl Cancer Inst. 2007 Jun 6;99(11):868-80. doi: 10.1093/jnci/djk199.
|
| 471 |
Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers.Prostate. 2013 Jan;73(2):182-93. doi: 10.1002/pros.22554. Epub 2012 Jul 10.
|
| 472 |
miRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation.Mol Oncol. 2018 Aug;12(8):1324-1341. doi: 10.1002/1878-0261.12328. Epub 2018 Jun 14.
|
| 473 |
Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk.Cancer Genet Cytogenet. 2002 Aug;137(1):1-7. doi: 10.1016/s0165-4608(02)00549-6.
|
| 474 |
Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer.J Urol. 2008 May;179(5):2020-4. doi: 10.1016/j.juro.2008.01.009. Epub 2008 Mar 20.
|
| 475 |
Screening of genetic and expression alterations of SRC1 gene in prostate cancer.Prostate. 2006 Sep 15;66(13):1391-8. doi: 10.1002/pros.20427.
|
| 476 |
Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer.J Biol Chem. 2004 Feb 20;279(8):7119-30. doi: 10.1074/jbc.M307649200. Epub 2003 Dec 8.
|
| 477 |
P21 activated kinase-1 (Pak1) promotes prostate tumor growth and microinvasion via inhibition of transforming growth factor expression and enhanced matrix metalloproteinase 9 secretion.J Biol Chem. 2013 Feb 1;288(5):3025-35. doi: 10.1074/jbc.M112.424770. Epub 2012 Dec 20.
|
| 478 |
Protocadherin-PC promotes androgen-independent prostate cancer cell growth.Prostate. 2006 Jul 1;66(10):1100-13. doi: 10.1002/pros.20446.
|
| 479 |
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.Nat Genet. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15.
|
| 480 |
Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.Anticancer Res. 2018 Nov;38(11):6361-6366. doi: 10.21873/anticanres.12994.
|
| 481 |
Somatic Mutations in Catalytic Core of POLK Reported in Prostate Cancer Alter Translesion DNA Synthesis.Hum Mutat. 2015 Sep;36(9):873-80. doi: 10.1002/humu.22820. Epub 2015 Jun 25.
|
| 482 |
Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer.Nat Commun. 2015 Oct 7;6:8469. doi: 10.1038/ncomms9469.
|
| 483 |
PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55/PP2A reconstitution that triggers centrosome destabilization.Oncogenesis. 2019 Dec 10;8(12):72. doi: 10.1038/s41389-019-0180-9.
|
| 484 |
EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2.Int J Cancer. 2005 Feb 10;113(4):561-7. doi: 10.1002/ijc.20612.
|
| 485 |
A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding.Nat Genet. 2014 Feb;46(2):126-35. doi: 10.1038/ng.2862. Epub 2014 Jan 5.
|
| 486 |
Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk.Cancer Res. 2008 Dec 15;68(24):10171-7. doi: 10.1158/0008-5472.CAN-08-1827.
|
| 487 |
Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels.Anticancer Res. 2008 Jan-Feb;28(1B):395-9.
|
| 488 |
ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer.Clin Cancer Res. 2008 Jun 15;14(12):3754-60. doi: 10.1158/1078-0432.CCR-07-4763.
|
| 489 |
Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.Prostate. 2007 Dec 1;67(16):1781-90. doi: 10.1002/pros.20665.
|
| 490 |
STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice.Cancers (Basel). 2019 Jul 2;11(7):929. doi: 10.3390/cancers11070929.
|
| 491 |
Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer.Oncotarget. 2019 Oct 22;10(58):6234-6244. doi: 10.18632/oncotarget.27263. eCollection 2019 Oct 22.
|
| 492 |
Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen. Cancer Genet Cytogenet. 2006 Apr 15;166(2):130-8. doi: 10.1016/j.cancergencyto.2005.09.012.
|
| 493 |
Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.J Clin Invest. 2018 Jan 2;128(1):248-266. doi: 10.1172/JCI92466. Epub 2017 Nov 27.
|
| 494 |
Progenitors from the central nervous system drive neurogenesis in cancer.Nature. 2019 May;569(7758):672-678. doi: 10.1038/s41586-019-1219-y. Epub 2019 May 15.
|
| 495 |
Dishevelled-2 silencing reduces androgen-dependent prostate tumor cell proliferation and migration and expression of Wnt-3a and matrix metalloproteinases.Mol Biol Rep. 2013 Jul;40(7):4241-50. doi: 10.1007/s11033-013-2506-6. Epub 2013 May 8.
|
| 496 |
The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.Oncotarget. 2016 Nov 22;7(47):76756-76768. doi: 10.18632/oncotarget.12525.
|
| 497 |
ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-B and drives prostate cancer progression.Cancer Res. 2013 Jul 15;73(14):4533-47. doi: 10.1158/0008-5472.CAN-12-4537. Epub 2013 May 16.
|
| 498 |
Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression.Front Genet. 2018 Dec 18;9:675. doi: 10.3389/fgene.2018.00675. eCollection 2018.
|
| 499 |
Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells.Cancer Biomark. 2018;22(3):533-541. doi: 10.3233/CBM-181196.
|
| 500 |
Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression.Prostate. 2013 Aug;73(11):1191-201. doi: 10.1002/pros.22667. Epub 2013 Apr 26.
|
| 501 |
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype.Oncogene. 2014 Nov 6;33(45):5274-87. doi: 10.1038/onc.2013.464. Epub 2013 Nov 18.
|
| 502 |
PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.Mol Cancer Res. 2012 Dec;10(12):1555-66. doi: 10.1158/1541-7786.MCR-12-0314.
|
| 503 |
Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer.Mol Cancer Res. 2011 Jan;9(1):36-50. doi: 10.1158/1541-7786.MCR-10-0158. Epub 2010 Dec 8.
|
| 504 |
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.J Clin Invest. 2011 Nov;121(11):4257-67. doi: 10.1172/JCI58509. Epub 2011 Oct 3.
|
| 505 |
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.Prostate. 2019 Jul;79(10):1156-1165. doi: 10.1002/pros.23830. Epub 2019 May 15.
|
| 506 |
RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans.Prostate. 2008 Mar 1;68(4):354-9. doi: 10.1002/pros.20687.
|
| 507 |
Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis.Anticancer Res. 2007 Mar-Apr;27(2):933-6.
|
| 508 |
Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.Prostate. 2005 Jun 1;63(4):316-23. doi: 10.1002/pros.20177.
|
| 509 |
Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells.FEBS Lett. 2004 Nov 19;577(3):451-4. doi: 10.1016/j.febslet.2004.10.044.
|
| 510 |
ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction.Cancer Res. 2008 Feb 15;68(4):1092-9. doi: 10.1158/0008-5472.CAN-07-2432.
|
| 511 |
Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 2007 Aug;9(8):643-51. doi: 10.1593/neo.07415.
|
| 512 |
The regulation of adiponectin receptors in human prostate cancer cell lines.Biochem Biophys Res Commun. 2006 Sep 29;348(3):832-8. doi: 10.1016/j.bbrc.2006.07.139. Epub 2006 Jul 31.
|
| 513 |
GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.Cancer Res. 2009 Feb 1;69(3):819-27. doi: 10.1158/0008-5472.CAN-08-2537. Epub 2009 Jan 27.
|
| 514 |
The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells.J Biol Chem. 2012 Dec 21;287(52):43862-75. doi: 10.1074/jbc.M112.407650. Epub 2012 Nov 1.
|
| 515 |
AIRE promotes androgen-independent prostate cancer by directly regulating IL-6 and modulating tumor microenvironment.Oncogenesis. 2018 May 25;7(5):43. doi: 10.1038/s41389-018-0053-7.
|
| 516 |
A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.Nat Genet. 2017 May;49(5):730-741. doi: 10.1038/ng.3817. Epub 2017 Mar 20.
|
| 517 |
Characterization of a novel human breast cancer associated gene (BCA3) encoding an alternatively spliced proline-rich protein.Biochim Biophys Acta. 2003 Jan 3;1625(1):116-21. doi: 10.1016/s0167-4781(02)00562-6.
|
| 518 |
No association of single nucleotide polymorphisms in one-carbon metabolism genes with prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3612-4. doi: 10.1158/1055-9965.EPI-08-0789.
|
| 519 |
Prostate cancer antigen-1 as a potential novel marker for prostate cancer.Asian J Androl. 2007 Nov;9(6):821-6. doi: 10.1111/j.1745-7262.2007.00279.x.
|
| 520 |
15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size).Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):135-46. doi: 10.1016/j.prostaglandins.2006.05.022. Epub 2006 Jul 7.
|
| 521 |
Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.Anticancer Res. 2008 Jul-Aug;28(4A):1977-83.
|
| 522 |
Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes.Cancer Immun. 2005 Dec 12;5:11.
|
| 523 |
Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.Int J Cancer. 2009 Dec 1;125(11):2528-39. doi: 10.1002/ijc.24592.
|
| 524 |
Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer.Prostate. 2004 Feb 1;58(2):103-8. doi: 10.1002/pros.10343.
|
| 525 |
The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates.Carcinogenesis. 2008 May;29(5):1077-82. doi: 10.1093/carcin/bgn069. Epub 2008 Mar 20.
|
| 526 |
The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.Mol Cancer Ther. 2016 Nov;15(11):2679-2687. doi: 10.1158/1535-7163.MCT-16-0225. Epub 2016 Aug 22.
|
| 527 |
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy.Cancer Biol Ther. 2007 Sep;6(9):1455-60. doi: 10.4161/cbt.6.9.4623. Epub 2007 Jun 23.
|
| 528 |
ASAP1, a gene at 8q24, is associated with prostate cancer metastasis.Cancer Res. 2008 Jun 1;68(11):4352-9. doi: 10.1158/0008-5472.CAN-07-5237.
|
| 529 |
Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours.Actas Urol Esp. 2017 Oct;41(8):529-534. doi: 10.1016/j.acuro.2016.11.009. Epub 2017 Mar 9.
|
| 530 |
ATPase family AAA domain containing 3A is an anti-apoptotic factor and a secretion regulator of PSA in prostate cancer.Int J Mol Med. 2011 Jul;28(1):9-15. doi: 10.3892/ijmm.2011.670. Epub 2011 Apr 6.
|
| 531 |
Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo.Amino Acids. 2012 Feb;42(2-3):549-58. doi: 10.1007/s00726-011-1032-x. Epub 2011 Sep 11.
|
| 532 |
Dynamic diffusion-weighted hyperpolarized (13) C imaging based on a slice-selective double spin echo sequence for measurements of cellular transport.Magn Reson Med. 2019 Mar;81(3):2001-2010. doi: 10.1002/mrm.27501. Epub 2018 Oct 28.
|
| 533 |
Analysis and sorting of prostate cancer cell types by flow cytometry.Prostate. 1999 Aug 1;40(3):192-9. doi: 10.1002/(sici)1097-0045(19990801)40:3<192::aid-pros7>3.0.co;2-f.
|
| 534 |
Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers.Prostate. 2006 Jun 1;66(8):801-10. doi: 10.1002/pros.20384.
|
| 535 |
Subnuclear domain proteins in cancer cells support the functions of RUNX2 in the DNA damage response.J Cell Sci. 2015 Feb 15;128(4):728-40. doi: 10.1242/jcs.160051. Epub 2015 Jan 20.
|
| 536 |
Analysis of candidate genes for prostate cancer.Hum Hered. 2004;57(4):172-8. doi: 10.1159/000081443.
|
| 537 |
Differential expression of osteocalcin during the metastatic progression of prostate cancer.Oncol Rep. 2009 Apr;21(4):903-8. doi: 10.3892/or_00000302.
|
| 538 |
Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma.Int J Cancer. 2000 Apr 15;86(2):155-61. doi: 10.1002/(sici)1097-0215(20000415)86:2<155::aid-ijc2>3.0.co;2-m.
|
| 539 |
Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase.J Biol Chem. 2006 Jul 14;281(28):19320-6. doi: 10.1074/jbc.M513203200. Epub 2006 May 1.
|
| 540 |
Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4.Oncogene. 2006 Mar 9;25(10):1446-53. doi: 10.1038/sj.onc.1209192.
|
| 541 |
Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway.Mol Cancer. 2006 Mar 1;5:9. doi: 10.1186/1476-4598-5-9.
|
| 542 |
Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.BMC Genomics. 2018 Jun 11;19(1):450. doi: 10.1186/s12864-018-4827-2.
|
| 543 |
Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer.Cancer Immunol Immunother. 2013 Dec;62(12):1811-9. doi: 10.1007/s00262-013-1486-7. Epub 2013 Oct 18.
|
| 544 |
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.J Natl Cancer Inst. 2008 Jul 16;100(14):1022-36. doi: 10.1093/jnci/djn214. Epub 2008 Jul 8.
|
| 545 |
The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis.BMC Cancer. 2006 Jul 21;6:195. doi: 10.1186/1471-2407-6-195.
|
| 546 |
Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines.J Urol. 1990 Jun;143(6):1272-4. doi: 10.1016/s0022-5347(17)40253-9.
|
| 547 |
Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase. J Cell Physiol. 2005 Aug;204(2):381-7. doi: 10.1002/jcp.20422.
|
| 548 |
Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.Cancer Res. 2008 May 15;68(10):3759-66. doi: 10.1158/0008-5472.CAN-07-1657.
|
| 549 |
PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells.Cancer Res. 2014 Oct 15;74(20):5795-807. doi: 10.1158/0008-5472.CAN-14-0872. Epub 2014 Sep 9.
|
| 550 |
C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.Prostate. 2005 May 1;63(2):143-54. doi: 10.1002/pros.20159.
|
| 551 |
Gene expression profiling predicts clinical outcome of prostate cancer.J Clin Invest. 2004 Mar;113(6):913-23. doi: 10.1172/JCI20032.
|
| 552 |
SRRM4 gene expression correlates with neuroendocrine prostate cancer.Prostate. 2019 Jan;79(1):96-104. doi: 10.1002/pros.23715. Epub 2018 Aug 28.
|
| 553 |
Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.Cancer Invest. 2009 May;27(4):369-75. doi: 10.1080/07357900802232749.
|
| 554 |
Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death.Int J Cancer. 2008 Aug 1;123(3):543-51. doi: 10.1002/ijc.23548.
|
| 555 |
Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis.Cancer Genet Cytogenet. 2005 Sep;161(2):97-103. doi: 10.1016/j.cancergencyto.2005.02.006.
|
| 556 |
Ubiquitylation of epsilon-COP by PIRH2 and regulation of the secretion of PSA.Mol Cell Biochem. 2008 Jan;307(1-2):73-82. doi: 10.1007/s11010-007-9586-3. Epub 2007 Aug 25.
|
| 557 |
The expression of inducible cAMP early repressor (ICER) is altered in prostate cancer cells and reverses the transformed phenotype of the LNCaP prostate tumor cell line.Cancer Res. 2001 Aug 15;61(16):6055-9.
|
| 558 |
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse.Cancer Res. 2003 Jul 15;63(14):4196-203.
|
| 559 |
Identification of extracellular delta-catenin accumulation for prostate cancer detection.Prostate. 2009 Mar 1;69(4):411-8. doi: 10.1002/pros.20902.
|
| 560 |
Increased nucleotide polymorphic changes in the 5'-untranslated region of delta-catenin (CTNND2) gene in prostate cancer.Oncogene. 2009 Jan 29;28(4):555-64. doi: 10.1038/onc.2008.399. Epub 2008 Nov 3.
|
| 561 |
Potential use of chymotrypsin-like proteasomal activity as a biomarker for prostate cancer.Oncol Lett. 2018 Apr;15(4):5149-5154. doi: 10.3892/ol.2018.7936. Epub 2018 Feb 2.
|
| 562 |
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3414-9. doi: 10.1073/pnas.0813144106. Epub 2009 Feb 13.
|
| 563 |
CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.Mol Cancer Res. 2008 Apr;6(4):546-54. doi: 10.1158/1541-7786.MCR-07-0277. Epub 2008 Mar 14.
|
| 564 |
The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2.J Biol Chem. 2002 Apr 12;277(15):12622-31. doi: 10.1074/jbc.M110568200. Epub 2002 Jan 25.
|
| 565 |
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.J Natl Cancer Inst. 2007 Dec 19;99(24):1836-44. doi: 10.1093/jnci/djm250. Epub 2007 Dec 11.
|
| 566 |
Downregulation of DACT-2 by Promoter Methylation and its Clinicopathological Significance in Prostate Cancer.J Cancer. 2019 Apr 20;10(7):1755-1763. doi: 10.7150/jca.28577. eCollection 2019.
|
| 567 |
Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia.Prostate. 2007 Sep 1;67(12):1308-17. doi: 10.1002/pros.20618.
|
| 568 |
Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression.Oncogene. 2013 May 2;32(18):2315-24, 2324.e1-4. doi: 10.1038/onc.2012.245. Epub 2012 Jun 25.
|
| 569 |
Genetic variants of the copy number polymorphic beta-defensin locus are associated with sporadic prostate cancer.Tumour Biol. 2008;29(2):83-92. doi: 10.1159/000135688. Epub 2008 Jun 2.
|
| 570 |
DGCR8 is essential for tumor progression following PTEN loss in the prostate.EMBO Rep. 2015 Sep;16(9):1219-32. doi: 10.15252/embr.201439925. Epub 2015 Jul 23.
|
| 571 |
Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease.Cancer Res. 2009 Jul 1;69(13):5601-9. doi: 10.1158/0008-5472.CAN-08-3860. Epub 2009 Jun 23.
|
| 572 |
Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.Cancer Genet Cytogenet. 2003 Jan 15;140(2):113-7. doi: 10.1016/s0165-4608(02)00674-x.
|
| 573 |
Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.Epigenetics Chromatin. 2016 Nov 9;9:50. doi: 10.1186/s13072-016-0102-4. eCollection 2016.
|
| 574 |
BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia.Mod Pathol. 2009 Jan;22(1):1-6. doi: 10.1038/modpathol.2008.168. Epub 2008 Oct 17.
|
| 575 |
Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression.Cancer Genet Cytogenet. 1999 Nov;115(1):65-9. doi: 10.1016/s0165-4608(99)00081-3.
|
| 576 |
Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion.Oncogene. 2001 May 17;20(22):2781-90. doi: 10.1038/sj.onc.1204379.
|
| 577 |
The Drg-1 gene suppresses tumor metastasis in prostate cancer.Cancer Res. 2003 Apr 15;63(8):1731-6.
|
| 578 |
Small integrin-binding proteins as serum markers for prostate cancer detection.Clin Cancer Res. 2009 Aug 15;15(16):5199-207. doi: 10.1158/1078-0432.CCR-09-0783. Epub 2009 Aug 11.
|
| 579 |
Upregulation and overexpression of DVL1, the human counterpart of the Drosophila dishevelled gene, in prostate cancer.Tumori. 2005 Nov-Dec;91(6):546-51. doi: 10.1177/030089160509100616.
|
| 580 |
EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer.Int J Cancer. 2003 Sep 1;106(3):310-5. doi: 10.1002/ijc.11205.
|
| 581 |
Transient reduction of PTI-1 expression by short interfering RNAs inhibits the growth of human prostate cancer cell lines.Tohoku J Exp Med. 2006 Jun;209(2):141-8. doi: 10.1620/tjem.209.141.
|
| 582 |
Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer.Br J Cancer. 2015 Feb 17;112(4):755-64. doi: 10.1038/bjc.2014.622. Epub 2015 Jan 29.
|
| 583 |
Genetic susceptibility loci, pesticide exposure and prostate cancer risk. PLoS One. 2013 Apr 4;8(4):e58195. doi: 10.1371/journal.pone.0058195. Print 2013.
|
| 584 |
GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells.Regul Pept. 2002 Nov 15;109(1-3):141-8. doi: 10.1016/s0167-0115(02)00197-0.
|
| 585 |
A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells.RNA. 2010 Jun;16(6):1156-66. doi: 10.1261/rna.2019810. Epub 2010 Apr 20.
|
| 586 |
Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia.J Endocrinol. 2017 Nov;235(2):123-136. doi: 10.1530/JOE-17-0112.
|
| 587 |
TCEB1 promotes invasion of prostate cancer cells.Int J Cancer. 2009 Jan 1;124(1):95-102. doi: 10.1002/ijc.23916.
|
| 588 |
Embigin Promotes Prostate Cancer Progression by S100A4-Dependent and-Independent Mechanisms.Cancers (Basel). 2018 Jul 23;10(7):239. doi: 10.3390/cancers10070239.
|
| 589 |
Knockdown of MBP-1 in human prostate cancer cells delays cell cycle progression.J Biol Chem. 2006 Aug 18;281(33):23652-7. doi: 10.1074/jbc.M602930200. Epub 2006 Jun 8.
|
| 590 |
Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer.Expert Opin Ther Targets. 2008 Jul;12(7):845-53. doi: 10.1517/14728222.12.7.845.
|
| 591 |
Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.J Urol. 2007 May;177(5):1753-8. doi: 10.1016/j.juro.2007.01.010.
|
| 592 |
Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res. 2009 Mar 1;69(5):1877-84. doi: 10.1158/0008-5472.CAN-08-2447. Epub 2009 Feb 17.
|
| 593 |
NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans.Prostate Cancer Prostatic Dis. 2008;11(4):349-56. doi: 10.1038/sj.pcan.4501027. Epub 2007 Nov 20.
|
| 594 |
Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers.Clin Cancer Res. 2009 Apr 15;15(8):2703-10. doi: 10.1158/1078-0432.CCR-08-2454. Epub 2009 Apr 7.
|
| 595 |
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.J Clin Invest. 2016 Feb;126(2):706-20. doi: 10.1172/JCI78132. Epub 2016 Jan 5.
|
| 596 |
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.Mol Endocrinol. 2007 Mar;21(3):613-24. doi: 10.1210/me.2006-0269. Epub 2006 Dec 27.
|
| 597 |
Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.Cancer Cell. 2019 Dec 9;36(6):674-689.e6. doi: 10.1016/j.ccell.2019.10.005. Epub 2019 Nov 14.
|
| 598 |
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.Cancer Cell. 2010 Jul 13;18(1):23-38. doi: 10.1016/j.ccr.2010.05.024.
|
| 599 |
Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells.Int J Oncol. 2004 Jan;24(1):97-105.
|
| 600 |
Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009 Feb 15;69(4):1527-35. doi: 10.1158/0008-5472.CAN-08-3609. Epub 2009 Feb 3.
|
| 601 |
Chromium(VI) promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer.Toxicol Lett. 2019 Jan;300:10-17. doi: 10.1016/j.toxlet.2018.10.012. Epub 2018 Oct 10.
|
| 602 |
CR6-interacting factor 1 represses the transactivation of androgen receptor by direct interaction.Mol Endocrinol. 2008 Jan;22(1):33-46. doi: 10.1210/me.2007-0194. Epub 2007 Sep 20.
|
| 603 |
miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF- signaling pathway.Biomed Pharmacother. 2018 Aug;104:637-644. doi: 10.1016/j.biopha.2018.05.041. Epub 2018 May 25.
|
| 604 |
Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer.Prostate. 2019 Oct;79(14):1629-1639. doi: 10.1002/pros.23887. Epub 2019 Aug 2.
|
| 605 |
A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion.J Biol Chem. 2006 Sep 8;281(36):26483-90. doi: 10.1074/jbc.M604376200. Epub 2006 Jun 20.
|
| 606 |
Expression of GnRH type II is regulated by the androgen receptor in prostate cancer.Endocr Relat Cancer. 2007 Sep;14(3):613-24. doi: 10.1677/ERC-07-0041.
|
| 607 |
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.Br J Cancer. 2008 Sep 16;99(6):939-48. doi: 10.1038/sj.bjc.6604614.
|
| 608 |
Increased expression of mitochondrial glycerophosphate dehydrogenase and antioxidant enzymes in prostate cancer cell lines/cancer.Free Radic Res. 2007 Oct;41(10):1116-24. doi: 10.1080/10715760701579314.
|
| 609 |
GPR75 receptor mediates 20-HETE-signaling and metastatic features of androgen-insensitive prostate cancer cells.Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Feb;1865(2):158573. doi: 10.1016/j.bbalip.2019.158573. Epub 2019 Nov 21.
|
| 610 |
Activator of G protein signaling 3 modulates prostate tumor development and progression.Carcinogenesis. 2019 Dec 31;40(12):1504-1513. doi: 10.1093/carcin/bgz076.
|
| 611 |
GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate. 2006 Jun 1;66(8):886-94. doi: 10.1002/pros.20403.
|
| 612 |
Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [(64)Cu]-DOTHA(2)-PEG-RM26.Nucl Med Biol. 2018 Jan;56:31-38. doi: 10.1016/j.nucmedbio.2017.10.006. Epub 2017 Oct 23.
|
| 613 |
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19226-31. doi: 10.1073/pnas.0700735104. Epub 2007 Nov 28.
|
| 614 |
CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.Oncogene. 2006 Aug 3;25(33):4559-72. doi: 10.1038/sj.onc.1209462. Epub 2006 Jun 19.
|
| 615 |
Use of a cryptic splice site for the expression of huntingtin interacting protein 1 in select normal and neoplastic tissues.Cancer Res. 2008 Feb 15;68(4):1064-73. doi: 10.1158/0008-5472.CAN-07-5892.
|
| 616 |
JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells.J Biol Chem. 2004 Apr 23;279(17):17090-100. doi: 10.1074/jbc.M307629200. Epub 2004 Feb 6.
|
| 617 |
Androgen receptor regulates CD168 expression and signaling in prostate cancer.Carcinogenesis. 2008 Feb;29(2):282-90. doi: 10.1093/carcin/bgm259. Epub 2008 Jan 3.
|
| 618 |
Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation.Cancer Res. 2009 Mar 15;69(6):2210-8. doi: 10.1158/0008-5472.CAN-08-2308. Epub 2009 Mar 3.
|
| 619 |
Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5207-E5215. doi: 10.1073/pnas.1617467114. Epub 2017 Jun 13.
|
| 620 |
HOXA10 expression profiling in prostate cancer.Prostate. 2019 Apr;79(5):554-563. doi: 10.1002/pros.23761. Epub 2019 Jan 6.
|
| 621 |
Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo. Gene. 2016 Sep 30;590(2):234-43. doi: 10.1016/j.gene.2016.05.009. Epub 2016 May 13.
|
| 622 |
PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation.Prostate. 2006 Jul 1;66(10):1092-9. doi: 10.1002/pros.20443.
|
| 623 |
Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.Curr Mol Med. 2017;17(1):70-78. doi: 10.2174/1566524017666170220104920.
|
| 624 |
Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One. 2009;4(3):e4830. doi: 10.1371/journal.pone.0004830. Epub 2009 Mar 13.
|
| 625 |
Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005 Feb 1;11(3):1028-36.
|
| 626 |
HRK inactivation associated with promoter methylation and LOH in prostate cancer.Prostate. 2008 Jan 1;68(1):105-13. doi: 10.1002/pros.20600.
|
| 627 |
Prostate tumor cell exosomes containing hyaluronidase Hyal1 stimulate prostate stromal cell motility by engagement of FAK-mediated integrin signaling.Matrix Biol. 2019 May;78-79:165-179. doi: 10.1016/j.matbio.2018.05.002. Epub 2018 May 10.
|
| 628 |
Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma.Clin Exp Metastasis. 2003;20(5):437-44. doi: 10.1023/a:1025419708343.
|
| 629 |
IFI16 in human prostate cancer.Mol Cancer Res. 2007 Mar;5(3):251-9. doi: 10.1158/1541-7786.MCR-06-0269. Epub 2007 Mar 5.
|
| 630 |
EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells.Cancer Res. 2003 May 15;63(10):2665-74.
|
| 631 |
Miz1, a Novel Target of ING4, Can Drive Prostate Luminal Epithelial Cell Differentiation.Prostate. 2017 Jan;77(1):49-59. doi: 10.1002/pros.23249. Epub 2016 Aug 16.
|
| 632 |
INPP4B suppresses prostate cancer cell invasion.Cell Commun Signal. 2014 Sep 25;12:61. doi: 10.1186/s12964-014-0061-y.
|
| 633 |
The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells.Clin Cancer Res. 2008 Jun 1;14(11):3562-70. doi: 10.1158/1078-0432.CCR-07-4649.
|
| 634 |
Role of the orphan nuclear receptor ROR alpha in the control of the metastatic behavior of androgen-independent prostate cancer cells.Oncol Rep. 2002 Sep-Oct;9(5):1139-43.
|
| 635 |
Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies.Oncogene. 2010 Feb 11;29(6):831-44. doi: 10.1038/onc.2009.399. Epub 2009 Nov 23.
|
| 636 |
Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.Prostate. 2009 May 15;69(7):727-36. doi: 10.1002/pros.20920.
|
| 637 |
Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.Cancer Sci. 2018 Nov;109(11):3564-3574. doi: 10.1111/cas.13776. Epub 2018 Sep 25.
|
| 638 |
A new human gene KCNRG encoding potassium channel regulating protein is a cancer suppressor gene candidate located in 13q14.3.FEBS Lett. 2003 Mar 27;539(1-3):156-60. doi: 10.1016/s0014-5793(03)00211-4.
|
| 639 |
JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis.Cancer Res. 2016 Feb 15;76(4):831-43. doi: 10.1158/0008-5472.CAN-15-0906. Epub 2016 Jan 8.
|
| 640 |
Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.Cancer Gene Ther. 2008 May;15(5):315-22. doi: 10.1038/cgt.2008.3. Epub 2008 Feb 15.
|
| 641 |
KIF7 attenuates prostate tumor growth through LKB1-mediated AKT inhibition.Oncotarget. 2017 Apr 26;8(33):54558-54571. doi: 10.18632/oncotarget.17421. eCollection 2017 Aug 15.
|
| 642 |
KLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1 accumulation.Mol Cancer. 2015 Apr 21;14:91. doi: 10.1186/s12943-015-0365-6.
|
| 643 |
Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.Tumour Biol. 2005 Nov-Dec;26(6):324-36. doi: 10.1159/000089290. Epub 2005 Oct 26.
|
| 644 |
Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone.PLoS One. 2016 Oct 6;11(10):e0163232. doi: 10.1371/journal.pone.0163232. eCollection 2016.
|
| 645 |
In vivo functional studies of tumor-specific retrogene NanogP8 in transgenic animals.Cell Cycle. 2013 Aug 1;12(15):2395-408. doi: 10.4161/cc.25402. Epub 2013 Jun 26.
|
| 646 |
Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration.Neoplasia. 2005 Apr;7(4):380-9. doi: 10.1593/neo.04619.
|
| 647 |
Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer.Prostate. 2003 Jun 15;56(1):30-6. doi: 10.1002/pros.10220.
|
| 648 |
DNA-based detection of prostate cancer in blood, urine, and ejaculates.Ann N Y Acad Sci. 2001 Sep;945:51-8. doi: 10.1111/j.1749-6632.2001.tb03863.x.
|
| 649 |
Multiple newly identified loci associated with prostate cancer susceptibility.Nat Genet. 2008 Mar;40(3):316-21. doi: 10.1038/ng.90. Epub 2008 Feb 10.
|
| 650 |
LAPSER1: a novel candidate tumor suppressor gene from 10q24.3.Oncogene. 2001 Oct 11;20(46):6707-17. doi: 10.1038/sj.onc.1204866.
|
| 651 |
Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.Mol Cancer Res. 2009 Apr;7(4):523-35. doi: 10.1158/1541-7786.MCR-08-0400.
|
| 652 |
MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.Prostate. 2018 Jun;78(8):616-622. doi: 10.1002/pros.23506. Epub 2018 Mar 14.
|
| 653 |
Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells.Cancer Res. 2006 Sep 1;66(17):8439-47. doi: 10.1158/0008-5472.CAN-06-1636.
|
| 654 |
Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell line.J Cell Sci. 2004 Oct 15;117(Pt 22):5343-51. doi: 10.1242/jcs.01420. Epub 2004 Oct 5.
|
| 655 |
Activation of pro-apoptotic p38-MAPK pathway in the prostate cancer cell line M12 expressing a truncated IGF-IR.Horm Metab Res. 2003 Nov-Dec;35(11-12):751-7. doi: 10.1055/s-2004-814160.
|
| 656 |
Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene.Oncogene. 2004 Mar 18;23(12):2241-9. doi: 10.1038/sj.onc.1207328.
|
| 657 |
PTOV1 antagonizes MED25 in RAR transcriptional activation.Biochem Biophys Res Commun. 2011 Jan 7;404(1):239-44. doi: 10.1016/j.bbrc.2010.11.100. Epub 2010 Nov 24.
|
| 658 |
MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.Clin Cancer Res. 2018 Aug 1;24(15):3668-3680. doi: 10.1158/1078-0432.CCR-17-3673. Epub 2018 May 1.
|
| 659 |
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.Anticancer Res. 2008 Jul-Aug;28(4A):1993-9.
|
| 660 |
Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression.Clin Cancer Res. 2006 May 1;12(9):2767-73. doi: 10.1158/1078-0432.CCR-05-1995.
|
| 661 |
Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor.Cell Res. 2006 Sep;16(9):750-8. doi: 10.1038/sj.cr.7310089.
|
| 662 |
The differentiation-related gene 1, Drg1, is markedly upregulated by androgens in LNCaP prostatic adenocarcinoma cells.FEBS Lett. 1999 Jul 16;455(1-2):23-6. doi: 10.1016/s0014-5793(99)00845-5.
|
| 663 |
The MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4-dependent migration of cancer cells.Sci Rep. 2018 Feb 2;8(1):2268. doi: 10.1038/s41598-018-20765-8.
|
| 664 |
Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells.Prostate. 2002 Jul 1;52(2):89-97. doi: 10.1002/pros.10097.
|
| 665 |
MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer.Clin Exp Metastasis. 2005;22(7):565-73. doi: 10.1007/s10585-005-5376-z. Epub 2006 Feb 11.
|
| 666 |
Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells.Prostate. 2001 May 15;47(3):194-204. doi: 10.1002/pros.1063.
|
| 667 |
Spatial genomic heterogeneity within localized, multifocal prostate cancer.Nat Genet. 2015 Jul;47(7):736-45. doi: 10.1038/ng.3315. Epub 2015 May 25.
|
| 668 |
Somatic mutation analysis of MYH11 in breast and prostate cancer.BMC Cancer. 2008 Sep 17;8:263. doi: 10.1186/1471-2407-8-263.
|
| 669 |
GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.Prostate. 2008 Sep 15;68(13):1387-95. doi: 10.1002/pros.20806.
|
| 670 |
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.Virology. 2004 Dec 5;330(1):34-49. doi: 10.1016/j.virol.2004.08.039.
|
| 671 |
MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3 signaling impedes castration-resistant prostate cancer growth.Aging (Albany NY). 2019 Nov 24;11(22):10644-10663. doi: 10.18632/aging.102482. Epub 2019 Nov 24.
|
| 672 |
Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.Oncogene. 2015 Jul;34(29):3839-47. doi: 10.1038/onc.2014.310. Epub 2014 Oct 6.
|
| 673 |
Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma.Hum Pathol. 2001 Sep;32(9):935-9. doi: 10.1053/hupa.2001.27102.
|
| 674 |
HIF induces human embryonic stem cell markers in cancer cells.Cancer Res. 2011 Jul 1;71(13):4640-52. doi: 10.1158/0008-5472.CAN-10-3320. Epub 2011 Jun 28.
|
| 675 |
hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.Am J Surg Pathol. 2008 Feb;32(2):205-9. doi: 10.1097/PAS.0b013e318124a865.
|
| 676 |
Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.Oncogene. 2004 Sep 2;23(40):6712-25. doi: 10.1038/sj.onc.1207772.
|
| 677 |
The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion.Mol Oncol. 2017 Jun;11(6):655-669. doi: 10.1002/1878-0261.12059. Epub 2017 May 2.
|
| 678 |
BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions.Int J Mol Sci. 2018 Jul 20;19(7):2104. doi: 10.3390/ijms19072104.
|
| 679 |
NOL8, the binding protein for beta-catenin, promoted the growth and migration of prostate cancer cells.Chem Biol Interact. 2018 Oct 1;294:40-47. doi: 10.1016/j.cbi.2018.08.019. Epub 2018 Aug 18.
|
| 680 |
Increased Nox1 and hydrogen peroxide in prostate cancer.Prostate. 2005 Feb 1;62(2):200-7. doi: 10.1002/pros.20137.
|
| 681 |
Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res. 2007 Nov-Dec;27(6B):3813-8.
|
| 682 |
TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3.Prostate. 2003 Oct 1;57(2):129-33. doi: 10.1002/pros.10282.
|
| 683 |
Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein.Oncogene. 2004 Apr 1;23(14):2499-506. doi: 10.1038/sj.onc.1207343.
|
| 684 |
Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis.Mol Carcinog. 2003 Mar;36(3):123-9. doi: 10.1002/mc.10108.
|
| 685 |
Com-1/p8 acts as a putative tumour suppressor in prostate cancer.Int J Mol Med. 2006 Nov;18(5):981-6.
|
| 686 |
PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer.Int J Cancer. 2006 Mar 15;118(6):1471-80. doi: 10.1002/ijc.21527.
|
| 687 |
Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate.J Biol Chem. 2011 Sep 23;286(38):33478-88. doi: 10.1074/jbc.M111.269894. Epub 2011 Jul 27.
|
| 688 |
Magmas expression in neoplastic human prostate.J Mol Histol. 2005 Feb;36(1-2):69-75. doi: 10.1007/s10735-004-3840-8.
|
| 689 |
The RNA-Binding Protein PCBP1 Functions as a Tumor Suppressor in Prostate Cancer by Inhibiting Mitogen Activated Protein Kinase 1.Cell Physiol Biochem. 2018;48(4):1747-1754. doi: 10.1159/000492315. Epub 2018 Aug 3.
|
| 690 |
Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells.Nucleic Acids Res. 2006;34(22):6684-95. doi: 10.1093/nar/gkl968. Epub 2006 Dec 1.
|
| 691 |
Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells.Oncotarget. 2017 Jun 28;8(48):83602-83618. doi: 10.18632/oncotarget.18787. eCollection 2017 Oct 13.
|
| 692 |
Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors.Cancer Res. 2001 Mar 15;61(6):2390-4.
|
| 693 |
Androgens down-regulate the expression of the human homologue of paternally expressed gene-3 in the prostatic adenocarcinoma cell line LNCaP.Mol Cell Endocrinol. 1999 Sep 10;155(1-2):69-76. doi: 10.1016/s0303-7207(99)00113-6.
|
| 694 |
Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.J Biol Chem. 2012 Feb 3;287(6):3610-6. doi: 10.1074/jbc.R111.318675. Epub 2011 Dec 5.
|
| 695 |
Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6018-22. doi: 10.1158/1078-0432.CCR-06-0625.
|
| 696 |
Effects of PTX1 expression on growth and tumorigenicity of the prostate cancer cell line PC-3.DNA Cell Biol. 2003 Jul;22(7):469-74. doi: 10.1089/104454903322247343.
|
| 697 |
Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia. 2008 Mar;10(3):279-86. doi: 10.1593/neo.07965.
|
| 698 |
Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression.Eur Urol. 2018 Mar;73(3):322-339. doi: 10.1016/j.eururo.2017.08.027. Epub 2017 Sep 18.
|
| 699 |
Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer.Epigenetics. 2014 Jun;9(6):918-27. doi: 10.4161/epi.28710. Epub 2014 Apr 2.
|
| 700 |
Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.Prostate. 2007 Feb 1;67(2):214-25. doi: 10.1002/pros.20522.
|
| 701 |
Brn-3a neuronal transcription factor functional expression in human prostate cancer.Prostate Cancer Prostatic Dis. 2006;9(1):83-91. doi: 10.1038/sj.pcan.4500837.
|
| 702 |
Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.Int J Mol Med. 2002 Aug;10(2):173-6.
|
| 703 |
Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.Cancer Genomics Proteomics. 2008 Mar-Apr;5(2):123-36.
|
| 704 |
PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.Mol Cancer Res. 2013 Jun;11(6):568-78. doi: 10.1158/1541-7786.MCR-12-0710. Epub 2013 Mar 14.
|
| 705 |
Biodistribution and Pharmacokinetic Evaluations of a Novel Taxoid DHA-SBT-1214 in an Oil-in-Water Nanoemulsion Formulation in Nave and Tumor-Bearing Mice.Pharm Res. 2018 Mar 8;35(4):91. doi: 10.1007/s11095-018-2349-x.
|
| 706 |
Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal. 2007 Feb;19(2):401-9. doi: 10.1016/j.cellsig.2006.07.011. Epub 2006 Jul 25.
|
| 707 |
ARP2 a novel protein involved in apoptosis of LNCaP cells shares a high degree homology with splicing factor Prp8.Mol Cell Biochem. 2005 Jan;269(1-2):189-201. doi: 10.1007/s11010-005-3084-2.
|
| 708 |
Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.J Cell Biochem. 2007 Jun 1;101(3):631-41. doi: 10.1002/jcb.21207.
|
| 709 |
Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth.Cancer Res. 2013 Nov 15;73(22):6574-83. doi: 10.1158/0008-5472.CAN-12-4692. Epub 2013 Sep 26.
|
| 710 |
Expression of prothymosin alpha is correlated with development and progression in human prostate cancers.Prostate. 2006 Apr 1;66(5):463-9. doi: 10.1002/pros.20385.
|
| 711 |
Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.J Exp Clin Cancer Res. 2019 Aug 6;38(1):341. doi: 10.1186/s13046-019-1349-y.
|
| 712 |
Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex.Cancer Res. 2008 Apr 15;68(8):2678-88. doi: 10.1158/0008-5472.CAN-07-6017.
|
| 713 |
Rad9 has a functional role in human prostate carcinogenesis.Cancer Res. 2008 Mar 1;68(5):1267-74. doi: 10.1158/0008-5472.CAN-07-2304.
|
| 714 |
Rap2 regulates androgen sensitivity in human prostate cancer cells.Prostate. 2007 Oct 1;67(14):1590-9. doi: 10.1002/pros.20644.
|
| 715 |
RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype.Cancer Res. 2010 Oct 15;70(20):7905-17. doi: 10.1158/0008-5472.CAN-09-4729. Epub 2010 Sep 28.
|
| 716 |
RASL11A, member of a novel small monomeric GTPase gene family, is down-regulated in prostate tumors.Biochem Biophys Res Commun. 2004 Apr 9;316(3):618-27. doi: 10.1016/j.bbrc.2004.02.091.
|
| 717 |
Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.Int J Cancer. 2008 Feb 15;122(4):952-6. doi: 10.1002/ijc.23196.
|
| 718 |
The Ras effector RASSF2 controls the PAR-4 tumor suppressor.Mol Cell Biol. 2010 Jun;30(11):2608-20. doi: 10.1128/MCB.00208-09. Epub 2010 Apr 5.
|
| 719 |
Characterization and Evidence of the miR-888 Cluster as a Novel Cancer Network in Prostate.Mol Cancer Res. 2018 Apr;16(4):669-681. doi: 10.1158/1541-7786.MCR-17-0321. Epub 2018 Jan 12.
|
| 720 |
Distinct roles for p107 and p130 in Rb-independent cellular senescence.Cell Cycle. 2008 May 1;7(9):1262-8. doi: 10.4161/cc.7.9.5945. Epub 2008 Mar 7.
|
| 721 |
CHC1-L, a candidate gene for prostate carcinogenesis at 13q14.2, is frequently affected by loss of heterozygosity and underexpressed in human prostate cancer.Int J Cancer. 2002 Jun 10;99(5):689-96. doi: 10.1002/ijc.10393.
|
| 722 |
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.Mol Cell Biol. 2006 Sep;26(17):6502-10. doi: 10.1128/MCB.00147-06.
|
| 723 |
RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells.Oncogene. 2006 Mar 9;25(10):1554-9. doi: 10.1038/sj.onc.1209186.
|
| 724 |
Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin. Int J Oncol. 2011 Apr;38(4):893-902. doi: 10.3892/ijo.2011.938. Epub 2011 Feb 9.
|
| 725 |
RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway.Cancer Res. 2009 Mar 1;69(5):2108-16. doi: 10.1158/0008-5472.CAN-08-3495. Epub 2009 Feb 24.
|
| 726 |
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events.Genes Dev. 2008 Aug 15;22(16):2172-7. doi: 10.1101/gad.1699608.
|
| 727 |
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.Eur Urol. 2007 Aug;52(2):455-63. doi: 10.1016/j.eururo.2006.11.020. Epub 2006 Nov 17.
|
| 728 |
Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer.Oncogene. 2019 Jun;38(25):5038-5049. doi: 10.1038/s41388-019-0774-x. Epub 2019 Mar 11.
|
| 729 |
Relaxin promotes prostate cancer progression.Clin Cancer Res. 2007 Mar 15;13(6):1695-702. doi: 10.1158/1078-0432.CCR-06-2492.
|
| 730 |
Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells.Int J Oncol. 2016 Jun;48(6):2619-28. doi: 10.3892/ijo.2016.3458. Epub 2016 Mar 24.
|
| 731 |
Small G-protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis.Prostate. 2005 Sep 1;64(4):332-40. doi: 10.1002/pros.20243.
|
| 732 |
A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth.J Biol Chem. 2002 Feb 15;277(7):4609-17. doi: 10.1074/jbc.M108312200. Epub 2001 Oct 22.
|
| 733 |
Ribosomal protein l19 is a prognostic marker for human prostate cancer.Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2061-5. doi: 10.1158/1078-0432.CCR-05-2445.
|
| 734 |
A novel component of the ubiquitin pathway, ubiquitin carboxyl extension protein 1 is overexpressed in prostate cancer.Int J Mol Med. 2005 Feb;15(2):183-96.
|
| 735 |
RPS7 promotes cell migration through targeting epithelial-mesenchymal transition in prostate cancer.Urol Oncol. 2019 May;37(5):297.e1-297.e7. doi: 10.1016/j.urolonc.2019.01.011. Epub 2019 Feb 6.
|
| 736 |
SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells.Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20793-8. doi: 10.1073/pnas.0710343105. Epub 2007 Dec 17.
|
| 737 |
Functional evidence implicating S100P in prostate cancer progression.Int J Cancer. 2008 Jul 15;123(2):330-339. doi: 10.1002/ijc.23447.
|
| 738 |
CSR1 suppresses tumor growth and metastasis of prostate cancer.Am J Pathol. 2006 Feb;168(2):597-607. doi: 10.2353/ajpath.2006.050620.
|
| 739 |
Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer.Mol Cancer Res. 2006 Mar;4(3):169-76. doi: 10.1158/1541-7786.MCR-05-0165.
|
| 740 |
SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.Cell Rep. 2015 Nov 10;13(6):1183-1193. doi: 10.1016/j.celrep.2015.09.083. Epub 2015 Oct 29.
|
| 741 |
Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression.Mol Cancer Res. 2019 Apr;17(4):845-859. doi: 10.1158/1541-7786.MCR-18-0638. Epub 2019 Jan 4.
|
| 742 |
Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer.J Hum Genet. 2005;50(10):507-515. doi: 10.1007/s10038-005-0285-1. Epub 2005 Sep 20.
|
| 743 |
Protease nexin 1 induces apoptosis of prostate tumor cells through inhibition of X-chromosome-linked inhibitor of apoptosis protein.Oncotarget. 2015 Feb 28;6(6):3784-96. doi: 10.18632/oncotarget.2921.
|
| 744 |
Molecular characterization of an MLL1 fusion and its role in chromosomal instability.Mol Oncol. 2019 Feb;13(2):422-440. doi: 10.1002/1878-0261.12423. Epub 2018 Dec 31.
|
| 745 |
Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.Mol Cancer Ther. 2006 Apr;5(4):903-12. doi: 10.1158/1535-7163.MCT-05-0393.
|
| 746 |
Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.Cancer Res. 2007 Oct 15;67(20):10087-96. doi: 10.1158/0008-5472.CAN-07-1646.
|
| 747 |
Prostate-specific membrane antigen.Prostate. 1997 Jul 1;32(2):140-8. doi: 10.1002/(sici)1097-0045(19970701)32:2<140::aid-pros9>3.0.co;2-q.
|
| 748 |
Bax-interacting factor-1 expression in prostate cancer.Clin Genitourin Cancer. 2008 Sep;6(2):117-21. doi: 10.3816/CGC.2008.n.018.
|
| 749 |
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3509-14. doi: 10.1073/pnas.0712269105. Epub 2008 Feb 26.
|
| 750 |
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells.Oncogene. 2008 Aug 28;27(37):5057-68. doi: 10.1038/onc.2008.143. Epub 2008 May 26.
|
| 751 |
GRIM-1, a novel growth suppressor, inhibits rRNA maturation by suppressing small nucleolar RNAs.PLoS One. 2011;6(9):e24082. doi: 10.1371/journal.pone.0024082. Epub 2011 Sep 8.
|
| 752 |
Reduced number of CD169(+) macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.Prostate. 2017 Nov;77(15):1468-1477. doi: 10.1002/pros.23407. Epub 2017 Sep 7.
|
| 753 |
The role of the transcription factor SIM2 in prostate cancer.PLoS One. 2011;6(12):e28837. doi: 10.1371/journal.pone.0028837. Epub 2011 Dec 9.
|
| 754 |
Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.Prostate. 2007 Feb 1;67(2):203-13. doi: 10.1002/pros.20521.
|
| 755 |
SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation.Histol Histopathol. 2008 Sep;23(9):1069-76. doi: 10.14670/HH-23.1069.
|
| 756 |
SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties.Mol Carcinog. 2019 Jan;58(1):113-125. doi: 10.1002/mc.22913. Epub 2018 Oct 5.
|
| 757 |
The PCAT3/PCAT9-miR-203-SNAI2 axis functions as a key mediator for prostate tumor growth and progression.Oncotarget. 2018 Jan 12;9(15):12212-12225. doi: 10.18632/oncotarget.24198. eCollection 2018 Feb 23.
|
| 758 |
Evolution of the androgen receptor pathway during progression of prostate cancer.Cancer Res. 2006 May 15;66(10):5012-20. doi: 10.1158/0008-5472.CAN-05-3082.
|
| 759 |
Sox7 negatively regulates prostate-specific membrane antigen (PSMA) expression through PSMA-enhancer.Prostate. 2019 Mar;79(4):370-378. doi: 10.1002/pros.23743. Epub 2018 Nov 28.
|
| 760 |
Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro.Int J Mol Med. 2007 Oct;20(4):613-9.
|
| 761 |
Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma.Endocr Relat Cancer. 2006 Sep;13(3):839-49. doi: 10.1677/erc.1.01190.
|
| 762 |
Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer.Prostate. 2006 May 1;66(6):613-24. doi: 10.1002/pros.20353.
|
| 763 |
Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. doi: 10.1158/1055-9965.EPI-10-0555. Epub 2010 Sep 14.
|
| 764 |
Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?.Prostate. 2013 May;73(7):743-53. doi: 10.1002/pros.22618. Epub 2013 Jan 28.
|
| 765 |
STAMP2 is required for human adipose-derived stem cell differentiation and adipocyte-facilitated prostate cancer growth in vivo.Oncotarget. 2016 Aug 9;8(54):91817-91827. doi: 10.18632/oncotarget.11131. eCollection 2017 Nov 3.
|
| 766 |
The Ste20 kinase MST4 plays a role in prostate cancer progression.Cancer Res. 2003 Jun 15;63(12):3356-63.
|
| 767 |
Pro-oncogene Pokemon Promotes Prostate Cancer Progression by Inducing STRN4 Expression.J Cancer. 2019 Apr 21;10(8):1833-1845. doi: 10.7150/jca.29471. eCollection 2019.
|
| 768 |
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.J Biol Chem. 2007 Dec 28;282(52):37341-9. doi: 10.1074/jbc.M706978200. Epub 2007 Oct 11.
|
| 769 |
Identification of a novel gene on chromosome 13 between BRCA-2 and RB-1.Prostate. 2001 May 1;47(2):91-101. doi: 10.1002/pros.1051.
|
| 770 |
TBC1D3, a hominoid oncoprotein, is encoded by a cluster of paralogues located on chromosome 17q12.Genomics. 2006 Dec;88(6):731-736. doi: 10.1016/j.ygeno.2006.05.009. Epub 2006 Jul 24.
|
| 771 |
PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer.Cancer Res. 2002 Oct 1;62(19):5420-4.
|
| 772 |
Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.Cell Mol Immunol. 2011 Sep;8(5):415-23. doi: 10.1038/cmi.2011.18. Epub 2011 Jun 13.
|
| 773 |
The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker.Prostate. 2016 Oct;76(14):1271-84. doi: 10.1002/pros.23213. Epub 2016 Jun 8.
|
| 774 |
Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene.Int J Cancer. 2004 Sep 20;111(5):798-804. doi: 10.1002/ijc.20337.
|
| 775 |
Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.Prostate. 2003 Sep 1;56(4):280-6. doi: 10.1002/pros.10262.
|
| 776 |
TGFBR3 loss and consequences in prostate cancer.Prostate. 2007 Feb 15;67(3):301-11. doi: 10.1002/pros.20526.
|
| 777 |
Association of TGIFLX/Y mRNA expression with prostate cancer.Med Oncol. 2009;26(1):73-7. doi: 10.1007/s12032-008-9086-7. Epub 2008 Jul 29.
|
| 778 |
Splice variants of TLE family genes and up-regulation of a TLE3 isoform in prostate tumors.Biochem Biophys Res Commun. 2007 Dec 28;364(4):918-23. doi: 10.1016/j.bbrc.2007.10.097. Epub 2007 Oct 26.
|
| 779 |
Transmembrane protein 64 modulates prostate tumor progression by regulating Wnt3a secretion.Oncol Lett. 2019 Jul;18(1):283-290. doi: 10.3892/ol.2019.10324. Epub 2019 May 6.
|
| 780 |
Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer.Nat Med. 1996 Dec;2(12):1322-8. doi: 10.1038/nm1296-1322.
|
| 781 |
2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6.Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):980-8. doi: 10.1158/1078-0432.CCR-05-2068.
|
| 782 |
Survey of differentially methylated promoters in prostate cancer cell lines.Neoplasia. 2005 Aug;7(8):748-60. doi: 10.1593/neo.05289.
|
| 783 |
Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.Prostate. 2009 Feb 15;69(3):327-35. doi: 10.1002/pros.20882.
|
| 784 |
Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.J Biol Chem. 2008 Feb 22;283(8):4834-40. doi: 10.1074/jbc.M708630200. Epub 2007 Dec 12.
|
| 785 |
Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer.Prostate. 2006 Feb 1;66(2):157-72. doi: 10.1002/pros.20328.
|
| 786 |
Sequence variants in the 3'-->5' deoxyribonuclease TREX2: identification in a genetic screen and effects on catalysis by the recombinant proteins.Adv Enzyme Regul. 2004;44:37-49. doi: 10.1016/j.advenzreg.2003.11.010.
|
| 787 |
A microsatellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness.Sci Rep. 2017 Dec 4;7(1):16862. doi: 10.1038/s41598-017-16700-y.
|
| 788 |
Expression profiles of androgen independent bone metastatic prostate cancer cells indicate up-regulation of the putative serine-threonine kinase GS3955.J Urol. 2004 Sep;172(3):1145-50. doi: 10.1097/01.ju.0000135117.40086.fa.
|
| 789 |
TRIM16 suppresses the progression of prostate tumors by inhibiting the Snail signaling pathway.Int J Mol Med. 2016 Dec;38(6):1734-1742. doi: 10.3892/ijmm.2016.2774. Epub 2016 Oct 17.
|
| 790 |
Marked gene transcript level alterations occur early during radical prostatectomy.Eur Urol. 2008 Feb;53(2):333-44. doi: 10.1016/j.eururo.2007.03.075. Epub 2007 Apr 9.
|
| 791 |
Cloning and characterisation of the RBCC728/TRIM36 zinc-binding protein from the tumor suppressor gene region at chromosome 5q22.3.Gene. 2004 May 12;332:45-50. doi: 10.1016/j.gene.2004.02.045.
|
| 792 |
TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells.Cancer Res. 2008 May 1;68(9):3486-94. doi: 10.1158/0008-5472.CAN-07-6059.
|
| 793 |
Proteomic analysis of proteins regulated by TRPS1 transcription factor in DU145 prostate cancer cells.Biochim Biophys Acta. 2007 May;1774(5):575-82. doi: 10.1016/j.bbapap.2007.03.011. Epub 2007 Mar 24.
|
| 794 |
Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.Microbiol Immunol. 2004;48(4):339-45. doi: 10.1111/j.1348-0421.2004.tb03515.x.
|
| 795 |
Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.Int J Oncol. 2009 Feb;34(2):457-63.
|
| 796 |
Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization.Cancer Res. 2006 Apr 15;66(8):4055-64. doi: 10.1158/0008-5472.CAN-05-3822.
|
| 797 |
Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.BMC Cancer. 2017 Feb 24;17(1):158. doi: 10.1186/s12885-017-3134-7.
|
| 798 |
Polyunsaturated fatty acids affect the localization and signaling of PIP3/AKT in prostate cancer cells.Carcinogenesis. 2013 Sep;34(9):1968-75. doi: 10.1093/carcin/bgt147. Epub 2013 Apr 30.
|
| 799 |
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
|
| 800 |
Conditional Deletion of Eaf1 Induces Murine Prostatic Intraepithelial Neoplasia in Mice.Neoplasia. 2019 Aug;21(8):752-764. doi: 10.1016/j.neo.2019.05.005. Epub 2019 Jun 21.
|
| 801 |
D-glucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells.Tumour Biol. 2014 Apr;35(4):3237-45. doi: 10.1007/s13277-013-1423-6. Epub 2013 Nov 22.
|
| 802 |
Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression.Mol Cancer. 2014 Mar 31;13:74. doi: 10.1186/1476-4598-13-74.
|
| 803 |
Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.Mol Cancer Ther. 2014 Jul;13(7):1813-25. doi: 10.1158/1535-7163.MCT-13-1004. Epub 2014 Apr 30.
|
| 804 |
SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas.PLoS One. 2013 Jul 30;8(7):e70558. doi: 10.1371/journal.pone.0070558. Print 2013.
|
|
|
|
|
|
|
